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Abstract 
Gamma-secretase is a trans-membrane aspartyl protease that consists of four subunits, 
namely Anterior Pharynx Defective Phenotype (APH-1), Presenilin (PSEN), Nicastrin 
(Nct) and Presenilin 2 Enhancer (PEN2). Presenilin is identified as the catalytic core of 
gamma-secretase with the two aspartyl residues at the catalytic site. Gamma-secretase is 
involved in the ultimate step in the processing of Amyloid Precursor Protein (APP) to 
yield Amyloid Beta peptide (Aβ).  Aβ of various residue lengths is formed that includes the 
toxic Aβ42. Aggregation of Aβ42 has been identified to contribute to etiology of 
Alzheimer’s disease (AD). Inhibition of processing of APP by gamma-secretase is a 
possible intervention strategy for the therapy for AD. Various studies carried out to find 
inhibitors for gamma-secretase have populated two classes of compounds, Gamma-
secretase Inhibitors (GSI) and Gamma-secretase Modulators (GSM). Despite these efforts 
there is a dearth of an effective therapy for AD. This study aimed to find potential 
inhibitors of gamma-secretase using in-silico screening of DrugBank database. A total of 
10 Pharmacophore models were developed from 54 molecules shown to inhibit gamma-
secretase. The pharmacophore models were used as 3D query in database screening of 
6160 drug molecules selected from DrugBank. The list of hits that resulted from the 
database screening using all the 10 pharmacophore models was compacted to yield 721 
unique entries with a fit score over 3.00 on a scale of 4.00 against the pharmacophore 
model. A QSAR model was developed employing multiple linear regression to calculate 
the predicted IC50 value for the 721 molecules from screening using pharmacophore 
models. Docking study was done to calculate the binding energy for 498 molecules with 
predicted IC50 value under 10000nM. 55 molecules with binding energy, ∆G, lesser than  
–8.00 kcal/mol are presented as potential inhibitors of gamma-secretase. Thus, this data 
can be used for further studies for the development of therapy for Alzheimer’s disease. 
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1 Introduction 
Proteins are the cogs that make the cell machinery tick. Proteins are involved in 
every aspect of cell function namely structure, motion, catalysis, recognition and 
regulation. The cellular membrane is embedded with membrane proteins that act as 
receptors, channels for a variety of molecules. These proteins thus enable signal 
transduction and transport of molecules into and out of the cell. Enzymes are proteins that 
act as catalysts in many processes and pathways in the cell. Also a number of enzymes are 
known to regulate various cellular processes and pathways by activating and deactivating 
other molecules involved in the processes. Antibodies are also proteins that are part of the 
immune response system that help to maintain immunity against foreign bodies. Signal 
transduction occurs due to the participation of trans-membrane proteins that act as 
receptor channels for the transport of the signaling molecules across the cell membrane. 
These are a few of the innumerous class of proteins involved in the complex machinery in 
the cell.  
 
1.1 Protein Folding and its regulation 
Self-assembly is one of the most intricate processes of the living system. A classic 
example of this self-assembly is the folding of proteins into three-dimensional structures. 
The bringing-together of the functional groups in vicinity to one-another in a highly 
specific structures result from protein folding aid in the possibility of diversity as well as 
selectivity in the chemical processes. Many biological activities are coupled to the correct 
folding of proteins that include molecular trafficking, regulation of growth and 
differentiation of the cell. Thus only a correctly folded protein has a long-term in the 
biological environment.  The most thermodynamically structures of proteins always 
correspond to the native state of the protein(1).  It is established that folding of a protein 
2 
 
does not involve the systemic search of all the possible conformations but a stochastic 
search of the conformations accessible to the chain of polypeptide(2). The right energy 
landscape, encoded by the amino acid sequence of the protein, which is in turn, is 
determined by the genetic code that has evolved for rapid and efficient folding of the 
protein, enables the scan of a small number of all possible conformations in order for the 
coil to transition into a native structure.  This energy landscape approach to protein 
folding shows that the transition states for folding are critical regions of energy surfaces 
through which all molecules must pass to reach the folded native state(3). 
The results of many studies show the formation of nucleus from a small number of 
residues, over which the rest of the structure condenses, as the fundamental mechanism of 
protein folding(4). An important element in the folding process is the formation of 
secondary structure that is stabilized by hydrogen bonding between the amide and 
carbonyl groups of the peptide main chain. Studies involving the structural properties of 
the intermediate or transition states show that a full native structure is obtained only when 
native-like interactions both within and between the domains have been formed(2). This is 
achieved by close packing and locking of side chains and exclusion of water molecules 
from protein core.  
Folding of proteins in vivo has been established to be co-transitional in a few 
cases, which implies that the protein synthesis and folding occur simultaneously. In other 
cases the proteins fold in the cytoplasm or after trafficking and translocation through the 
membranes in mitochondria or the endoplasmic reticulum. In order to regulate the folding 
of proteins several molecular chaperones present in the cell are brought into play. These 
molecular chaperones interact with the nascent chain of protein as soon as they emerge 
from the ribosomes or later. Molecular chaperones do not act as catalysts for the steps in 
protein folding but increase the effectiveness of these steps by reducing the probability of 
3 
 
the competing reactions such as aggregation.  The mechanism of action of the chaperones 
can be illustrated with the chaperonin GroEL and its co-chaperone Gro-ES. These have 
been shown to protect the protein from the external environment by allowing the 
incompletely folded protein to enter its cavity and then fold into native structure(5). It is 
also suggested that molecular chaperones are able to rescue misfolded proteins and 
aggregated proteins enabling them to have another chance at folding correctly. Also 
available are a class of folding catalysts such as protein disulfide isomerases, peptidylprolyl 
isomerases(6). The proteins destined for secretion undergo a quality control check in the 
endoplasmic reticulum. The mechanism of quality control involves glycosylation and 
deglycosylation reactions to enable correctly folded proteins to be distinguished from 
misfolded proteins.   The incorrectly folded proteins initiate an ‘unfolded protein response’ 
in which they are ubiquitinated and then degraded by proteasomes in the cytoplasm. 
 
1.2 Protein Misfolding and Amyloidogenesis 
It is understood that proteins need to be folded correctly to survive in the cell and 
carry out its function. It is also evident that both folding and unfolding are taken as ways 
of generating and abolishing cellular activities. The precursor to the protein degradation is 
unfolding(7). An intrinsic property of proteins is misfolding that happen continuously and 
is influenced by the sequence of amino acids. .Mutations in the amino acid sequence are 
said to accelerate misfolding. In addition, environmental changes such as increased 
temperature, low or high pH, presence of oxidative reagents or high glucose level cause the 
loss of native conformation in proteins rapidly, while being termed denaturation. This 
results in unfolding of the protein. The unfolded proteins are not functional. Also the 
unfolded state is thermodynamically unstable and unfavorable. In an attempt to seek lower 
energy level and higher stability, these proteins have aggregation propensity.  Aggregation 
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starts with nucleation in which the proteins attach reversibly onto a core that is growing, 
termed the nucleus, followed by irreversible attachment of proteins once the critical mass 
of the nucleus crosses the threshold to form a larger aggregate. The concentration of the 
monomers also determines the onset of aggregation. When the concentration of the 
monomer is low, the monomeric state is favored while at high concentration the 
aggregated state is favored as it presents a large energy barrier for resolution (8). Thus the 
aggregates are highly stable. Protein segments that have hydrophobic residues, low net 
charge and susceptibility to β-sheet formation are thought to initiate aggregation (9), by 
acting as the precursor cores that facilitate aggregation further. The precursor is generated 
from the native structure by means of introduction of misfolded variant, incorrect or 
incomplete proteolysis. Thus, there is introduction of a precursor pool from the partial 
misfolding of the variant protein from which rapid aggregation occurs. 
The structure of the protein aggregates vary from unordered amorphous 
aggregates to highly ordered fibrils. These highly ordered fibrils are termed as amyloid. The 
amyloid conformation is stable yet reversible. The amyloids are rich in cross-β structure. It 
consists of non-branched, linear fibrils of protein or peptide. X-ray analysis revealed that 
the β strands are arranged perpendicular to the fibril axis(10). Recent studies reveal the 
presence of parallel(11) or antiparallel(12) β-sheet conformation. Thus, confirming that 
amyloids fibrils have no universal tertiary and quaternary structures. Amyloids show 
conformational plasticity by adopting more than one stable tertiary fold due to which 
conformational differences exist within the fibril formed from a single polypeptide.  
Amyloid proteins are believed to be non-functional proteins while in some 
instances have been associated with physiological function, for example, fibrils of curlin in 
Escherichia coli mediate binding of bacterium to host. A large number of proteins, tau, 
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amyloid β, prion, insulin, α-synuclein and lysozyme to name a few, have been identified to 
undergo misfolding to form amyloids and result in misfolding diseases.  
1.3 Amyloidoses 
The group of protein misfolding diseases where there is accumulation of protein 
aggregates systemically or locally in certain tissues or organs is termed amyloidosis.  The 
characteristic feature of the amyloidoses is the presence of plaques or inclusion bodies. 
The conditions for the development of the disease are not yet fully studied.  These diseases 
can be systemic or localized based on the location of occurrence of the protein aggregates. 
The symptoms depend on the protein involved and the site or organ or aggregation of the 
protein. Diagnosis of the diseases requires histological analysis followed by the definition 
of the amyloidosis. Efficient therapy is not available for most of the amyloidoses.  
It is evident that the aggregates from proteins and peptides can be toxic to the cells 
or deviate from the function of the native protein. The amyloid fibrillar aggregates were 
earlier thought to be involved in the pathogenesis of a number of amyloidoses. Evidence 
has been piling-up on the involvement of the prefibrillar aggregates(13), oligomers(14) and 
not-native monomers(15) in exhibition of toxicity in the cells or tissues. Despite the lack of 
complete mechanism of various diseases and the cause for toxicity to cells or tissue, it can 
be said that the conversion proteins from soluble to insoluble state results in a population 
of non-native structures. The toxicity of these misfolded species tends to arise from the 
fact that the hidden groups that are normally buried are exposed and dispersed. Small 
aggregates are relatively more toxic that mature fibrils as these have a higher proportion of 
surface residues(16). These non-native structures are supposed to trigger a number of 
uncharacteristic events on its interaction with the various molecules and components of 
the cell. Hence are likely to cause malfunction in the cell machinery resulting in the 
diseased condition. Also the damage to the architecture of the tissue brought forward by 
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the accumulation of the aggregates is supposed to be the reason of pathogenesis in a few 
diseases(17).  
A number of human diseases have been classified as amyloidoses namely 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Dementia with Lewy 
bodies, lysozyme amyloidosis, fibrinogen amyloidosis, AA amyloidosis, AL amyloidosis, 
cataract and cutaneous lichen amyloidosis.  
1.4 Alzheimer’s disease and gamma secretase 
Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys 
memory and thinking skills, and eventually even the ability to carry out the simplest tasks. 
In most people with Alzheimer’s, symptoms first appear after age 60. It was estimated that 
35.6 million around the world may have Alzheimer’s disease in 2010; 65.7 million by 2030 
and 115.4 million by 2050(18). Alzheimer’s disease is the most common cause of dementia 
among older people. Dementia is the loss of cognitive functions which ranges in severity 
from mild to aggressive. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a 
woman who had died of an unusual mental illness. Her symptoms included memory loss, 
language problems, and unpredictable behavior. After she died, he examined her brain and 
found many abnormal clumps (now called amyloid plaques), tangled bundles of fibers 
(now called neurofibrillary tangles) and the loss of connections between nerve cells 
(neurons) in the brain. Hence, Alzheimer’s disease is named after Dr. Alois Alzheimer.   
In Alzheimer’s disease, senile plaques are formed by accumulation of aggregates of 
40- to 42-amino acid long, 39- and 43-aa peptides have also been described, amyloid-β 
(Aβ) peptide. Amyloid-β is formed by cleaving amyloid precursor protein (APP) by β- and 
γ-secretases. The cleavage of APP by γ-secretase produces a 42 amino acid Aβ-42 or a 40 
amino acid Aβ-40 is formed when it occurs in endoplasmic reticulum or trans-Golgi 
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network respectively. APP is involved in various physiological functions while that of Aβ 
peptide have not yet been deduced. In 1991, David Allsop and John Hardy proposed the 
amyloid cascade theory (ACH), according to which the amyloid-β peptide aggregate into 
protein assemblies, which in turn deposit into plaques in the brain that cause 
neurotoxicity(19).  
1.5 Therapy for Alzheimer’s disease 
The current treatments for Alzheimer’s disease are mostly symptomatic, while 
disease-modifying agents are emerging. The symptomatic or palliative treatments attempt 
to compensate for the decreased activity of cholinergic neurons. Various classes of 
compounds such as choline donors (4-Aminopyridine), cholinergic agonists (nicotine 
analogs) and acetyl choline esterase (AChE) inhibitors (donezepil, rivastigmine, 
galantamine) have been developed. The disease modifying drugs are developed to decrease 
the concentration of Aβ. This is done by inhibition of β- and γ- secretases. Also Aβ can be 
degraded or excreted and cleared from the cell to decrease its concentration in theory. In 
another approach the aggregation of Aβ can be inhibited. Inhibition of tau protein’s 
hyperphosphorylation by inhibiting the enzymes involved namely tau protein kinase I and 
II, extracellular signal-regulated kinase. Also drugs are also being developed that inhibit 
excitotoxicity (propiracetam, oxiracetam, or aniracetam) or act as antioxidants (trans-
resveratol, EGb761, Clioquinol). Thus there is a need for the increased effort in the 
development of therapy for Alzheimer’s disease. 
1.6 In-silico screening in drug discovery 
Drug discovery process consists of several steps namely target identification, lead 
compound screening, lead optimization, ADMET studies, preclinical trial evaluation, 
clinical trials and registration. This process trails behind due to being time-consuming, 
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expensive and inefficient due to the low rate of novel therapeutic discovery. In order to 
increase the overall efficiency of the process new methodologies and technologies are 
being implemented. Computational methods are employed in various areas of research. It 
is estimated that the implementation of computational methods in drug discovery can cut 
the annual cost by 33% and the time required by 30% for developing a new drug. 
Computational techniques are capable of providing information regarding function 
prediction, pathway information, homologue mapping, structural information, chemical 
information and disease association. Also a vast number of resources are available such as 
databases of chemical molecules such as ChEMBL, Therapeutic Target Database (TTD), 
Potential Drug Target Database (PDTD), PubChem, ChEMBLdb, DrugBank and etc. 
In-silico screening or virtual screening has become an established technique for the 
development of hit lead compounds. Virtual screening complements traditional high-
throughput screening (HTS) assays. This technique can act as a filter by eliminating a vast 
majority of non-binding compounds in-silico thereby reducing the number of compounds 
to be tested in vitro, thus, reducing the investment of resources in the early stages of drug 
discovery. It includes a series of techniques such as simple filtering and pharmacophore 
searches to docking and scoring. In-silico screening starts from a database of real 
compounds or a virtual database.  
1.7 Pharmacophore modeling 
A pharmacophore can be described as set of steric and electronic properties 
required for a compound to bind to an active site. It describes the three-dimensional 
arrangement of molecular features. The components of a pharmacophore model are 
hydrogen bond donors, hydrogen bond acceptors, aromatic rings, hydrophobic centers, 
acidic groups, basic groups, planar atoms, positive charge centers, negative charge centers, 
etc.  
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Pharmacophore modeling is the identification of various components of the 
pharmacophore and definition of the components to forma model. Pharmacophore 
modeling can be divided into structure-based and ligand-based approaches. Structure 
based pharmacophore modeling is construction of model from available structural data.  It 
can be further divided into macromolecule-ligand complex based and macromolecule 
based. Thus a pharmacophore model can be developed from a set of active compounds 
without any knowledge of the protein active site or from the active site of the protein 
when the geometry of the active site is available. This model can be used to search a 
compound database, which can hence be screened. 
1.8 Quantitative Structure-Activity Relationship (QSAR) 
QSAR is a way of finding a simple equation that can predict an unknown property 
from the molecular structure of a compound. This is done by curve fitting to find the 
equation coefficients that are weights for known molecular properties termed descriptors. 
A descriptor can be any number that describes some aspect of the molecule. The property 
that is being predicted is termed as activity. A QSAR model is essentially an equation that 
can be developed by various methods such as multiple linear regression, partial least 
squares, linear discriminant analysis, logistic regression, genetic function approximation, k-
nearest neighbor, feed forward back propagation neural network, general regression neural 
network and support vector regression. 
1.9 Docking method 
Docking is the search for the energetically favorable binding pose of a ligand to a 
macromolecular receptor. The aim of the docking program is to accurately predict the 
structure of the ligand-receptor complex enabling the prediction of the binding free energy 
of the complex. Docking has enabled the search through databases of available chemical 
10 
 
compounds for ligands to use as therapeutics or in studies. The molecule preparation must 
be performed before docking; it involves the creation of complete molecular model from 
molecular structure file followed by processing of the structure for use in specific docking 
program. The sampling method generates multiple positions of the ligand within the 
receptor such that the ligand is placed using the constraints of the receptor shape and are 
near minimum-energy positions. The three classes of sampling method are rigid ligand 
docking, flexible ligand docking and flexible receptor docking. The scoring method is used 
to compute the binding energy of a ligand to the receptor. The accuracy of the scoring 
function inversely affects the speed of calculation. Thus it is necessary to find a balance in 
choosing the method to be employed. 
1.10 Objective of the study 
The major objectives of the study are 
 To find the potential inhibitors of gamma secretase by screening of a chemical 
database 
 To develop pharmacophore models for use a query to screen the chemical 
database 
 To compute the specific activity of the hits of database screening using 
pharmacophore models 
 To subject a set of compounds filtered based on the predicted specific activity 
to docking study against the receptor, here gamma secretase 
 To put forward a set of compounds filtered based on binding energies 
computed using docking study as potential inhibitors of gamma secretase 
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2 Literature Review 
Alzheimer’s disease is a neurodegenerative disorder where the affected individuals 
exhibit dementia. Affected individuals exhibit progressive and permanent decline in 
memory and cognitive functions. It is difficult to positively diagnose Alzheimer’s disease in 
the early stages as memory loss can have other causes too. However a consistent pathology 
with amyloid aggregates called ‘plaques’ and neurofibrillary tangles, is observed in the brain 
of individuals affected by Alzheimer’s disease(20). These are found in the temporal 
neocortex and hippocampal regions of the affected individual’s brain(21). Of the different 
forms of Alzheimer’s disease the most common form occurs after 6o years of age and is 
sporadic(22). The other form of AD, Familial Alzheimer’s disease (FAD) has onset before 
60 years of age (22). The brain regions involved in learning and memory process of the 
individuals with AD are reduced in size. The areas for episodic memory, attention, 
executive functions, semantic memory, language and spatial orientation deteriorate as the 
disease progresses(23, 24). 
The amyloid plaques and neurofibrillary tangles result from the deposition of 
amyloid-β peptide and hyperphosphorylated tau protein, which lead to neuronal loss and 
neurotoxicity in the affected brain. The mechanism of induction of neurotoxicity by the 
deposition of Aβ peptide is not clear. Oxidative stress is stimulated by Aβ peptide directly 
and indirectly. Aβ peptide reduces metal ions to produce hydrogen peroxide by acting as 
enzymes and also generating free radicals (25-27). Aβ peptide also produces free radicals 
by binding to mitochondrial proteins (28). Aβ peptides generate oxidative stress through 
neuroinflammation. Astrocytes and microglia are activated and participate in the immune 
response to the deposition of amyloid beta peptide. These brain cell types produce reactive 
oxygen species upon activation in addition to chemokines and cytokines leading to cell 
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death(29). Aβ peptide also stimulates microglial cells to produce reactive nitric oxide, by 
inducing the expression of nitric oxide synthase(30), and quinolinic acid, a neurotoxin(31). 
Aβ peptide is produced by the processing of amyloid precursor protein (APP) by 
proteolysis. It then accumulates and eventually deposits into amyloid plaque in the brain. 
This is a primary event in the pathogenesis of AD (22). Along with the secondary events 
namely activation of microglia and astrocytes and formation of neurofibrillary tangles the 
formation of amyloid plaques result in neuronal dysfunction and loss. This hypothesis is 
termed as amyloid cascade hypothesis (ACH)(32). APP is a type I integral membrane 
protein that is expressed widely. It is expressed by the APP gene located on chromosome 
21. It is produced in different isoforms from 695 to 770 amino acids. It is processed by 
secretase enzymes to produce Aβ peptide in two distinct pathways, amyloidogenic and 
non-amyloidogenic. In amyloidogenic pathway the cleavage of soluble APP by β-secretase 
gives soluble β-APP, which are released in to the extracellular matrix(33). It is followed by 
the cleavage of the C-terminal fragment (C99) by γ-secretase which releases Aβ peptide of 
varying lengths with Aβ-40 and Aβ-42 being the most common forms. In non-
amyloidogenic pathway, soluble APP is cleaved by α-secretase to release α-APP into the 
extra-cellular matrix. The cleavage of the resulting C-terminal fragment (C83) by γ-
secretase produces p3 fragment(34). Aβ-42 exists as a monomer, which undergoes 
oligomerisation to form oligomers, proto-fibrils and fibrils.  Aβ-42 aggregates into β-sheet 
fibrillar state or non-β-sheet non-fibrillar state(35, 36). The oligomeric intermediate species 
and the mature fibrils are neurotoxic(37). 
Research has identified the genes responsible for the pathologies namely the 
amyloid precursor protein (APP) and the presenilins, PS1 and PS2 (PSEN1, PSEN2)(38). 
PS1 is central to the γ-secretase complex that cleaves APP and Notch(39). Mutations in 
these genes have been identified in Familial Alzheimer’s disease (FAD). These account for 
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50% of the FAD cases(40).The pathological features of FAD is similar to sporadic AD, 
hence mutations in APP, PSEN1, PSEN2 may have a role in sporadic AD too. So far 33 
mutations in APP, 185 mutations in PSEN1, 13 mutations in PSEN2 have been 
documented at the Alzheimer Disease & Frontotemporal Dementia Mutation 
Database(41) (http://www.molgen.vib-ua.be/ADMutations).  
γ-secretase is a transmembrane aspartyl protease. It exists in the plasma membrane 
as a mature complex. It is a multiprotein complex consisting of Presenilin, Nicastrin, Aph-
1 and Pen-2. It may possess homogeneous activity, as several alternatively spliced variants 
and paralogs of Presenilin and Aph-1 have been identified, or heterogeneous activity. The 
presenilins (PS) form the active catalytic core of the enzyme. PS1 and PS2 are the 
homologs of presenilin that exist in mammals. These have a molecular weight around 
50kDa.  It spans the cellular membrane several times. It has been identified that two 
aspartyl residues Asp 257 and Asp 385 located on transmembrane domains 6 and 7 
respectively are central to the catalytic activity of the enzyme(42). Presenilins are 
synthesized as precursor proteins that are incorporated into a larger complex for 
stabilization. This is accompanied by a proteolytic cleavage of PS by presenilinase(43). This 
results in the formation of two separate fragments N-terminal fragment (NTF) and C-
terminal fragment (CTF). Each has a molecular weight of ~ 30kDa and ~20kDa 
respectively. The second member of the complex Nicastrin (Nct) is a glycosylated 
membrane protein that binds to PS. It is synthesized as a precursor that is transported by 
PS from the endoplasmic reticulum and is required for the stabilization of PS NTF and 
CTF(44). Aph-1 is a multimembrane spanning protein with a molecular weight ~30kDa. It 
is necessary for the transport of Nct to cell surface(45). Pen-2 is a hairpin-like membrane 
protein with a molecular weight of approximately 12kDa(46). The molecular weight of the 
γ-secretase complex is on debate, with estimates from 200-250kDa(47) to ~440kDa(48) 
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and larger. All the four proteins are necessary for the full proteolytic activity of the 
enzyme. Genetic studies or knockdown studies on one or more of the components caused 
the loss of activity of the enzyme. Overexpression of one or more of the proteins but not 
all had no effect on the activity of the enzyme. Overexpression of all the component 
proteins caused a change in the proteolytic activity (48-50). 
In an attempt to develop therapy for Alzheimer’s disease, the proteolytic cleavage 
of APP by γ-secretase has been targeted in various studies. This led to the development 
and discovery of a number of compounds that inhibit or modulate the activity of γ-
secretase. Gamma-secretase inhibitors inhibit the activity of gamma-secretase on not only 
APP but other substrates as well. Administration of potent gamma-secretase inhibitors to 
APP transgenic mice resulted in gastrointestinal toxicity due to the disruption of Notch 
signaling in the ileum(51). Thus the development of compounds that are specific for the 
cleavage of APP was necessary. This gave rise to the class of compounds called gamma-
secretase modulators which spared the cleaving of Notch by gamma-secretase. 
γ-secretase inhibitors include compounds of various classes. These include 
transition state analogs, dipeptidic inhibitors, sulfonamides, kinase inhibitor, NSAIDs(52). 
L-685,458(53), WPE-31-C, LY450139(54), DAPT(55), Imatinib(56), R-flurbiprofen(56), 
sulindac sulfide(57), AZ1136, AZ3303, AZ4800(58), E2012(59), MRK-560 are the 
compounds that belong to the mentioned classes. Also studies have shown potent γ-
secretase inhibitors that include α-hydroxycarbonyl derivatives(60), aryl sulfones(61), 
compounds based on benzobicyclo[4.2.1]nonane core(62), helical D-tridecapeptides(63), 
derivatives of triterpene glycoside(64, 65), fused oxadiazines(66), derivatives of piperidine 
acetic acid(67), azepine derivatives(68) and cyclohexanones(69). The listed are only a 
segment of the compounds that have been reported. The mechanism of inhibition of 
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many of these compounds has not yet been fully understood. Meanwhile the search for 
new drugs utilizing various techniques is continuing. 
Drug discovery and development consists of several steps. It starts with the pre-
discovery, which is necessary to understand the pathogenesis of the disease and the 
pathways involved. It is a knowledge acquiring process which is crucial for treating the 
problem. Then target identification follows in which the molecule that is involved in the 
disease is identified as target that can be affected by a drug molecule. Finally, drug 
discovery begins with the testing of various molecules to find a lead molecule. This has 
been carried out by finding compounds in nature, de novo synthesis of molecules, high-
throughput screening. Lead compounds are tested for Absorption, Distribution, 
Metabolism, Excretion and Toxicological properties. Lead compounds are optimized to 
better its properties. This is done by testing analogues of the leads, leading to the choosing 
of the candidate drug. Also considered are the formulation, delivery mechanism and large-
scale manufacturing. Pre-clinical testing of the candidate drug involves in-vitro and in-vivo 
tests these include testing on animals. The clinical trials take place in four phases. In the 
first phase the drug is tested for safety in humans by testing on healthy human volunteers. 
The drug is tested on a small group of patients in the second phase of clinical trials. The 
third clinical trial phase is extensive where the safety and efficacy of the drug are tested. 
Then the drug is registered for approval with the authority for drug approval. It is followed 
by the final clinical trial phase where it is prescribed to a larger section of the population. 
Computational methods have been taken up for the drug discovery process. This 
has resulted in the faster and less expensive drug discovery. The availability of 
cheminformatics resources such as chemical compound databases, target structure 
databases, in addition to the computational techniques such as molecular modeling, 
molecular simulation, etc. has favored the trend of computational drug discovery. One of 
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the most time and resource consuming processes in drug discovery is screening for hits 
and lead compounds. The advent of virtual or in silico screening aimed at changing that. 
An integral part of drug discovery of late is virtual screening. Virtual screening was 
introduced recently compared to the use of database searching. It was defined as 
‘automatically evaluating very large libraries of compounds’ using computer programs(70). 
This suggests that a library of >1060 compounds can be filtered to manageable number 
using in-silico or virtual screening, while the focus in practical scenarios is on filtering 
combinatorial libraries of targeted compounds and enriched libraries. The success of an in-
silico screen lies in finding new or interesting structures than many hits. Availability of 
datasets, in-silico screening techniques and successful screening techniques has helped this 
method gain attention. The possibility of rapid identification of novel ligands(71), 
biomolecules from natural products(72) have improved this interest.  
Virtual screening can be structure-based(73) or ligand-based(74). Ligand based 
approach is primarily used when the protein structure is absent, while structure-based 
approach is used in the presence of high atomic resolution structural data of the protein. 
Results of various studies indicate that structure-based and ligand-based approaches can 
yield a better result when applied in concert(75, 76). Recently, the successful screening for 
the target MEK1 was reported. It employed both in silico and in vitro methods to identify 
fragments. This result has been suggested for use in drug discovery project(77). In another 
study, a library of small molecules was screened to find drugs that can be combined with 
highly active antiretroviral therapy (HAART) to reactivate dormant viruses. Similarity 
based search was employed to the hits of the screen resulting in the find of 8-methoxy-6-
methylquinolin-4-ol (MMQO) as a successful hit(78). Docking, fragment based search are 
structure-based approaches, while pharmacophore search, QSAR are ligand based 
approaches of in silico screening. 
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Pharmacophore was introduced and defined by Paul Ehrlich in 1909 (79) as ‘ a 
molecular framework that carries the essential features responsible for a drug’s biological 
activity’. It is defined by IUPAC(80) as ‘an ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with the biological target and 
to trigger ( or block ) its biological response’. Superposing a set of active molecules and 
extracting the common chemical features required for bioactivity or probing the 
interaction points between the ligand and the macromolecular target can give a 
pharmacophore model. It is being extensively used in in silico screening as well as de novo 
design.  
Structure-based and ligand-based are the two approaches for pharmacophore 
modeling. Ligand based pharmacophore modeling facilitates the drug discovery in the 
absence of the macromolecule structure. Pharmacophore generation from multiple ligands, 
termed training set, involves creating the conformational space for each ligand in the 
training set to represent conformational flexibility of ligands, and aligning the multiple 
ligands in the training set and determining the essential common chemical features to 
construct pharmacophore models. Structure based pharmacophore modeling involves the 
use of 3D structure of the macromolecular target. Its protocol starts with the analysis of an 
analysis of the complementary chemical features of the active site and their spatial 
relationships, and a subsequent pharmacophore model assembly with selected features. It 
can be further classified into macromolecule–ligand-complex based and macromolecule 
(without ligand)-based. A number of pharmacophore generator programs are available 
namely GASP(81), DISCO(82), HipHop(83), Hypogen(84), GALAHAD, PHASE(85), 
MOE, LigandScout(86), Pocket(87) and GBPM(88) besides a number of academic 
programs. On modeling of a pharmacophore model from a set of active ligands it can be 
used a template to query a 3D chemical database and search for potential ligands termed 
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hits. This approach faces the challenge of higher false positives and or higher false 
negative. This can be overcome by model optimization by adjusting the tolerance radius 
and position of each pharmacophoric feature. 
QSAR stands for Quantitative Structure-Activity Relationship that describes 
structure-activity relationship in terms of steric properties and physiochemical parameters 
or certain structural features. Thus QSAR can correlate inhibition constants, rate 
constants, and affinities of ligands to binding sites with in a series of compounds. The 
properties of the compounds are termed as descriptors. Lipophilicity, polarizability are 
molecular descriptors. Enzyme inhibition data of the compounds has been studied by 
correlating with physiochemical properties using QSAR. QSAR is based on the 
assumption that different structural properties contribute in a linear additive manner to its 
biological activity. There are several methods available to develop a QSAR model the most 
common being multiple linear regression. In an investigation of inhibition of dihydrofolate 
reductase (DHFR) from E. coli and L. casei by benzylpyrimidines, two equations (QSAR 
models) were generated one for each organism. These models differed on the contribution 
of five substituents of benzyl group to biological activity. This was explained to be due to 
the presence of rigid leucine residue on L. casei DHFR hence it formed a narrow cleft that 
the methionine residue in E. coli DHFR(89). 
Molecular descriptors have been extensively used in deriving structure-activity 
relationships, quantitative structure activity relationships, and machine learning prediction 
models for pharmaceutical agents.  A descriptor is “the final result of a logical and 
mathematical procedure which transforms chemical information encoded within a 
symbolic representation of a compound into an useful number or the result of some 
standardized experiment”. Many programs e.g. PaDEL-descriptor, DRAGON, Molconn-
Z, MODEL, Chemistry Development Kit (CDK), JOELib and Xue descriptor set are 
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available to calculate physical and chemical descriptors. These methods can be applied to 
derive >3,000 molecular descriptors. These descriptors include constitutional descriptors, 
topological descriptors, RDF descriptors, molecular walk counts, 3D-MoRSE descriptors, 
BCUT descriptors, WHIM descriptors, Galvez topological charge indices and charge 
descriptors, GETAWAY descriptors, 2D autocorrelations, functional groups, atom-
centered descriptors, aromaticity indices, Randic molecular profiles,  electrotopological 
state descriptors, linear solvation energy relationship descriptors, and other empirical and 
molecular properties. 
Docking and scoring are used to identify potential lead candidates. The algorithms 
generate a subset of a collection of compounds with higher affinity against a target 
macromolecule by predicting their binding mode and affinity. Docking algorithms deal 
with the prediction of ligand conformation and orientation with in the specific binding site 
of the receptor. DOCK(90), FlexX(91), GOLD(92), Glide(93), ICM(94), FRED(95) and 
AutoDock(96) are a few of the docking programs available in addition the web-based 
docking  servers. Scoring methods attempt to estimate the bound receptor-ligand complex 
rightness.  Scoring methods make assumptions and oversimplify various physical 
characteristics. This results in the inability of the scoring function to differentiate between 
correct and incorrect poses. Thus giving rise to a number of false positives and false 
negative hits. Docking based screening has been successfully implemented in finding the 
inhibitor for Acetylcholinesterase(97). The initial screening was done for the ACD and 
Maybridge database consisting of 160,000 compounds. The computer program used was 
ADAM & EVE. 
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3 Methods 
3.1 Dataset Collection 
The choice of training set is important to the pharmacophore generation process 
as the pharmacophore built is as good as the input data. The following criteria have been 
considered during the selection of data set. All the compounds have to bind to the same 
receptor more or less in the same fashion. The compound data should be widely populated 
over a larger activity range. The most active compounds have to be included in the dataset. 
All biologically relevant data should be obtained for the compounds(84). Each individual 
feature in the resulting pharmacophore will contribute a certain weight proportional to its 
contribution to biological activity. Taking in to account these criteria, 369 gamma-secretase 
inhibitors were sourced from various literature sources and the target database at 
ChEMBL (60-63, 65, 66, 98-109). The 2D structure of the compounds were obtained from 
ChEMBL chemical database(103). 2D structures were converted to 3D structures using 
OpenBabel 2.3.1(110). Next, the compounds were filtered based on No. of violations of 
Lipinski’s rule of five=0 which yielded 206 compounds. Also on filtering compounds with 
IC50 value < 100nM in a range of 0.08nM to 93nM, 56 compounds were obtained. These 
56 compounds were chosen as training set. The chemical structure of the compounds in 
the training set is given in (Figure 1), while their experimental activity (IC50) is given in 
(Table 1) 
3.2 Feature Mapping 
Pharmacophore features are chemical features such as hydrogen bond donors, 
hydrogen bond acceptors, aromatic rings, hydrophobic centers, acidic groups, basic 
groups, planar atoms, CO2 centroid, NCN+ centroid, etc. Pharmacophore features were 
mapped for 56 compounds of the training set using the Feature Mapping protocol in 
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Discovery Studio 2.5(111) The total no. of pharmacophore features among the 
compounds ranged from 8 to 28.(Table 2)  
3.3 Pharmacophore modeling  
The training set consisting of 56 compounds was used to generate pharmacophore 
model. The HipHop(83) Algorithm available in Common Feature Pharmacophore 
Generation protocol tries to generate pharmacophore hypothesis (models) with features 
common amongst the molecules of the training set. During pharmacophore generation a 
minimum of 1 and a maximum of 10 pharmacophore feature such as hydrogen bond 
donor (HBD), hydrogen bond acceptor (HBA), and hydrophobic (HY) were included. All 
the parameters were set to default. The HipHop algorithm scores each configuration based 
on both the degree to which it is common to the input set and its estimated rarity. The 
program begins by identifying configurations of features common to the molecules. More 
precisely, a configuration is a set of relative locations in 3D space, each associated with a 
type of feature. A molecule matches a configuration if it possesses a set of features and a 
conformation such that the set of features can be superimposed with the corresponding 
locations. A set of features is considered superimposed if each feature lies within a 
specified distance, the tolerance, from the corresponding ideal location. Certain molecules 
may be permitted to miss a feature until the total no. of molecules missing a feature does 
not drop below the set limit. The hypotheses are scored by classic maximum likelihood 
rule based on the probability of observed data under the assumption that the hypothesis is 
correct. The rarity of a configuration is estimated by applying regression model for perfect 
matches to the sub configuration including features in a subset. The algorithm can also 
optionally use information from inactive ligands to place excluded volume features. The 
HipHop algorithm reports the 10 top-scoring hypotheses until there is no improvement in 
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the hypothesis score. The resulting 10 pharmacophore hypotheses were used for the later 
steps of screening. 
3.4 Database Selection 
The database selected was DrugBank(112). DrugBank is a freely available web-
enabled database that combines detailed drug data with comprehensive drug-target and 
drug-action information. It was specifically designed to facilitate in silico drug-target 
discovery, drug design, drug-metabolism prediction, drug-interaction prediction, and 
general pharmaceutical education. The database contains 6264 molecules drug entries 
including 1465 FDA-approved small molecule drugs, 132 FDA-approved biotech 
(protein/peptide) drugs, 86 nutraceuticals and 5076 experimental drugs. Since the 
screening is to be carried out to aid in the discovery of drugs for Alzheimer’s disease, 
DrugBank was chosen as all the molecules will exhibit drug like property. All the available 
drug structures were used for the in-silico screening study. The structures of the drugs 
were downloaded in .sdf (Structural data file) format from the web database for use in the 
screening. 
3.5 Local Database Creation 
Database was created on the local workstation using the Build 3D database 
protocol in Discovery Studio 2.5. 6264 molecules were input for database creation. The 
database building was done with default parameters, except the conformation method was 
changed to FAST to get quick diverse low-energy conformations. During the building 
process 104 molecules showed error related to valency requirement or parsing error, hence 
were not included in the database created. Thus the final database created consisted of 
6160 molecules.  
 
23 
 
Figure 1 - Structure of compounds in training set. The two-dimensional chemical structure of 
56 compounds taken in the training set. The ChEMBL Id for the compounds has been used to 
denote the compounds. 
 
CHEMBL51698 CHEMBL51699 CHEMBL57146 CHEMBL58925 CHEMBL73841 CHEMBL115852 
CHEMBL117978 CHEMBL118450 CHEMBL119657 CHEMBL130093 CHEMBL133746 CHEMBL177969 
CHEMBL179519 CHEMBL180209 CHEMBL182327 CHEMBL182349 CHEMBL183449 CHEMBL183558 
CHEMBL183585 CHEMBL183654 CHEMBL183764 CHEMBL183777 CHEMBL191302 CHEMBL194084 
CHEMBL194422 CHEMBL194788 CHEMBL196523 CHEMBL198302 CHEMBL199570 CHEMBL199912 
CHEMBL200176 CHEMBL200503 CHEMBL200664 CHEMBL200864 CHEMBL200913 CHEMBL210279 
CHEMBL211896 CHEMBL291322 CHEMBL291976 CHEMBL332885 CHEMBL333710 CHEMBL336071 
CHEMBL362216 CHEMBL366022 CHEMBL369557 CHEMBL370107 CHEMBL371754 CHEMBL372156 
CHEMBL379089 CHEMBL379758 CHEMBL382060 CHEMBL383826 CHEMBL384207 CHEMBL406322 
CHEMBL421236 CHEMBL431679 
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Table 1 - Training dataset for pharmacophore modelling for potential inhibitors of gamma-
secretase showing experimental activity (IC50) and the total no. of pharmacophore 
features (Note - Exp.-Experimental, P.-Pharmacophore) 
Compound Id 
Exp. 
IC50 
(nM) 
No. of 
P. 
features 
CHEMBL51698 15 14 
CHEMBL51699 93 14 
CHEMBL57146 32 8 
CHEMBL58925 1 15 
CHEMBL73841 6.9 13 
CHEMBL115852 57 11 
CHEMBL117978 5 11 
CHEMBL118450 47 11 
CHEMBL119657 86 11 
CHEMBL130093 0.49 14 
CHEMBL133746 13.2 13 
CHEMBL177969 50 10 
CHEMBL179519 15 20 
CHEMBL180209 1 19 
CHEMBL182327 34 16 
CHEMBL182349 41 19 
CHEMBL183449 70 12 
CHEMBL183558 7 20 
CHEMBL183585 75 18 
CHEMBL183654 50 15 
CHEMBL183764 12 20 
CHEMBL183777 62 16 
CHEMBL191302 27 14 
CHEMBL194084 18 19 
CHEMBL194422 17 16 
CHEMBL194788 1 20 
CHEMBL196523 19 19 
CHEMBL198302 3.4 19 
Compound Id 
Exp. 
IC50 
(nM) 
No. of 
P. 
features 
CHEMBL199570 1.9 11 
CHEMBL199912 1.1 13 
CHEMBL200176 1 10 
CHEMBL200503 1.3 10 
CHEMBL200664 4.2 20 
CHEMBL200864 4.2 26 
CHEMBL200913 10.7 19 
CHEMBL210279 6.18 28 
CHEMBL211896 55 10 
CHEMBL291322 29 13 
CHEMBL291976 71 26 
CHEMBL332885 38 11 
CHEMBL333710 14 11 
CHEMBL336071 1.8 15 
CHEMBL362216 29 16 
CHEMBL366022 22 10 
CHEMBL369557 5 20 
CHEMBL370107 10 19 
CHEMBL371754 0.82 18 
CHEMBL372156 35 9 
CHEMBL379089 0.08 26 
CHEMBL379758 77 10 
CHEMBL382060 1 12 
CHEMBL383826 4.7 18 
CHEMBL384207 0.9 24 
CHEMBL406322 4 10 
CHEMBL421236 76 13 
CHEMBL431679 5 17 
25 
 
3.6 Database Screening 
Instead of selecting a single pharmacophore hypothesis from the 10 hypotheses 
generated, all the pharmacophore hypotheses were used for screening the database created 
from the molecules obtained from DrugBank. The purpose of this screening is to retrieve 
hits for further screening. The database screening was carried out using Search 3D 
database protocol of Catalyst in Discovery Studio 2.5 with the query as the individual 
pharmacophore hypotheses; with default parameters except the search method was 
changed to FAST allowing a rigid fit of the ligand conformation against the 
pharmacophore. Thus 10 lists of compounds each corresponding to a pharmacophore 
could be obtained. Then a list with unique entires and entries with a Fit Value > 3.00 was 
prepared by merging all the lists of compounds obtained by screening DrugBank 
compounds with the pharmacophore as query. 
3.7 Activity prediction using QSAR 
The compounds in the training set were selected based on the available activity 
data i.e., experimental IC50 values. IC50 is the half maximal inhibitory concentration. It is 
a measure of effectiveness of a compound in inhibiting a biological function. It 
quantitatively gives the concentration of the drug or inhibitor required for the inhibition of 
a given biological process by half. FDA terms IC50 as the concentration of the drug 
required for 50% inhibition in vitro. IC50 can be related to affinity for competitive 
agonists and antagonists even though it is not direct indicator of affinity. The activity of 
the compounds (IC50) in the training set was for the production of Aβ-42 by cleaving of 
APP by gamma-secretase. Since the mechanism of action of gamma-secretase is known, 
the compound inhibits this biological process. The IC50 for the screened compound can 
be predicted by developing a QSAR model with the activity data of the training set of 
pharmacophore modeling as training set for QSAR model development. It is understood 
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that the development of a QSAR model which is a linear mathematical equation relating 
the biological activity of interest with the molecular descriptors of the compounds in the 
test set (unknown). 
3.8 Calculation of Molecular descriptors 
Molecular descriptors are required to be calculated for both the training set and the 
test set. The molecular descriptors were calculated for the compounds using e-Dragon 
tool. This tool can calculate over 3000 molecular descriptors which is lesser compared to 
the standalone dragon software. It required the input of the structure of the compound in 
SMILES or .sdf. The molecular descriptors were given as tab separated values. These were 
calculated and documented for both the test set and the training set. Some of the 
molecular descriptors calculated include number of rings (nCIC), number of rotable bonds 
(RBN), mean atomic polarizability (Mp), etc.  
3.9 Selection of Molecular descriptors 
The following molecular descriptors were selected from the list of over 3000 
descriptors. Sum of atomic van der Waals volumes (Sv), mean atomic van der Waals 
volume (Mv), mean atomic Sanderson electronegativity (Me), mean atomic polarizability 
(Mp), number of bonds (nBT), number of rings (nCIC), hydrophilic factor (Hy), 
Moriguchi octanol-water partition coefficient (MLogP) and Ghose-Crippen octanol-water 
partition coefficient (ALogP). Thus a total of nine molecular properties were selected. The 
no. of molecular properties is one-fifth of the number of compounds in the training set. 
This is because multiple linear regression is employed to develop the QSAR model to 
predict the biological activity of the test set of compounds. The reason behind this could 
be understood from the following theory on multiple linear regression. 
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3.10 Multiple Linear Regression 
Multiple linear regression is the most commonly employed method for 
constructing QSAR models. It is also a simple method. A multiple linear regression model 
is constructed with the assumption that a linear relationship exists between a set of 
molecular descriptors of a compound and a specific activity. The molecular descriptors are 
represented by a feature vector x with each descriptor as its component while the activity is 
represented by a quantity y.  The following equation is a description of multiple linear 
regression model. 
𝑦 = 𝛼0 + 𝛼1𝑋1 + 𝛼2𝑋2 + ⋯ . . +𝛼𝑛𝑋𝑛 
where 𝛼0 is the regression model constant, (𝑋1, 𝑋2, ….., 𝑋𝑛) are molecular descriptors, 
𝛼1 to 𝛼2 are the coefficients for the individual descriptors from 𝑋1 to 𝑋𝑛 . The values for 
𝛼0  to 𝛼𝑛  are chosen by minimizing the sum of squares of the residuals between the 
observed and predicted values defined by the equation so as to give the best prediction of 
𝑦 from x. This method has the advantage of having a simplistic form and being an easy 
interpretable expression. The positive or negative contribution of the molecular 
descriptors from 𝛼1 to 𝛼𝑛 is indicated by the sign of their respective coefficients. The 
relative importance of every descriptor to that activity is given by its magnitude. However, 
multiple linear regression works well only when the structure-activity relationship is linear 
in nature, the set of molecular descriptors are mathematically independent (orthogonal) of 
each another and the number of compounds in the training set exceeds the number of 
molecular descriptors by at least a factor of five. It has been found that, when collinear 
descriptors are used, the derived coefficients 𝛼1 to 𝛼𝑛  tend to be larger than the real 
values and sometimes have opposite signs. Therefore, the assumption of a linear 
relationship between a set of molecular descriptors and a specific activity may not always 
be appropriate, especially in the cases involving multiple mechanisms. 
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3.11 Developing QSAR model to predict IC50 
QSAR model was developed by using the tool EasyQSAR v1.0. It uses the 
statistics engine of Microsoft Excel to perform the regression analysis. This requires the 
input of experimental biological data. In order to keep the mean deviation in the data of 
biological data as small as possible log IC50 is given as biological activity. The values of the 
molecular descriptors are fed in the tool. After performing the regression analysis the 
QSAR model that is a linear mathematical equation is given.  
The QSAR model was then tested by substituting the test set molecular descriptor 
data in it. This was be used to validate the QSAR model by comparing the predicted and 
experimental activity data. Then the IC50 values were be predicted for the test set by 
substituting the values for the molecular descriptors in the QSAR model. The predicted 
IC50 values were used to filter the compounds for further screening.  
3.12 Docking study with SwissDock 
Docking study was carried out to find the binding of the ligand to the receptor. 
The challenge to carry out the study was the absence of complete three-dimensional 
structure of gamma-secretase complex. Sourcing of databases revealed the availability of 
structural data for the C-terminal fragment (CTF) of presenilin [PDB ID: 2KR6]. It had 
been identified that the catalytic core of the gamma-secretase complex is presenilin. The 
catalytic site of presenilin includes two aspartyl residues Asp 257 and Asp 285 on the 6th 
and 7th transmembrane domains respectively. The Asp 285 is present in the CTF of 
presenilin. Thus a compound that binds to Asp 285 or in the vicinity of Asp 285, block the 
binding of the substrate making it geometrically impossible. This involved the 
identification of binding site that possess Asp 285 using QsiteFinder tool(113).  The 
geometric co-ordinates of the binding site with Asp 285 were predicted by the tool. 
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The compounds obtained after the filtering based on predicted IC50 values were 
used in docking study. The docking study was carried out using SwissDock(114). 
SwissDock is an EADock DSS(115) based web server. The algorithm consists of the 
following steps generation of binding modes wither in box or in the vicinity of all target 
cavities, estimation of CHARMM energies on a grid, evaluation of binding modes with 
most favorable energies and clustered, visualization of the favorable clusters. It allows the 
docking of protein receptor with ligand molecules. It requires the input format of the 
receptor to be .pdb (Protein Data Bankk) and that or ligand to be .mol2. These file format 
conversion were done using OpenBabel 2.3.1. The ligand and receptor files, minimized 
energetically, in the appropriate format were uploaded to the web-based server for docking 
study. The results contained the estimated free energy of binding (∆G) and Full fitness 
score, besides the conformation of the ligand docked to the receptor. The lower estimated 
free energy of binding indicates the higher binding affinity. The compounds were again 
screened based on the estimated free energy of binding. The screening hits are suggested 
as potential inhibitors of gamma-secretase. 
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4 Results 
4.1 Pharmacophore Modeling  
The resulting pharmacophore hypotheses generated using the training set of active 
gamma-secretase inhibitors had a max fit score of 4 with rank ranging from 249.565 to 
256.150 with the pharmacophore features hydrophobic center (HY) and hydrogen bond 
acceptor (HBA) and a total of 4 features. The configuration of the pharmacophore 
hypotheses are presented in (Figure 2) while (Table 2) gives the details of each hypothesis.  
Table 2 - Pharmacophore hypotheses generated with the features present in the 
pharmacophore model and the maximum fit score along with the rank of each hypotheses. 
Pharmacophore 
hypotheses Features Rank Max Fit 
01 HY HY HBA HBA 256.150 4 
02 HY HY HBA HBA 253.297 4 
03 HY HY HBA HBA 252.572 4 
04 HY HY HBA HBA 252.518 4 
05 HY HY HBA HBA 251.107 4 
06 HY HY HBA HBA 251.098 4 
07 HY HY HBA HBA 251.004 4 
08 HY HY HBA HBA 250.902 4 
09 HY HY HBA HBA 250.813 4 
10 HY HY HBA HBA 249.565 4 
 
HY – Hydrophobic center, HBA – Hydrogen Bond Acceptor 
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Figure 2 - Pharmacophore hypotheses generated. The input of 56 training set molecules 
gave 10 pharmacophore hypotheses. The pharmacophore hypotheses have hydrophobic, HY 
(cyan) and hydrogen bond acceptor, HBA (green). The total no. of features in each hypothesis 
is 4 (2 HY, 2 HBA). 
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4.2 Database Screening 
4.2.1 Pharmacophore search 
The screening of 6160 compounds from DrugBank with the pharmacophore 
hypotheses as query resulted in a reduced number of molecules than in total number of 
molecules in the database. No one hypotheses could be used alone as all the models had 
the same type of and the same number of pharmacophore features. Each hypothesis 
namely hypothesis 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 produced 1270, 1206, 1431, 1373, 1696, 
1372, 1682, 1569, 1433 and 1832 hits in the screening process. The merging of the 
compound lists into another list with only compounds with fit value above 3.00 and 
unique entries contained 721 compounds. This list along with the fit value of the 
molecules is given in (Table 3) 
4.3 Activity prediction using QSAR 
The training set consisting of 54 compounds with experimental activity data (IC50) 
and molecular descriptor data was used to develop QSAR model. The training set 
compounds along with their experimental activity and with molecular descriptor data is 
given in (Table 4). EasyQSAR tool yielded a QSAR model upon input of data and 
followed by analysis. The following model was developed and can be used to predict IC50 
of the 721 compounds in the test set. The QSAR model was validated by substituting the 
values of the training set in it. Thus the difference in experimental and predicted data was 
obtained. The values are given in (Table 6). The molecular descriptors of the compounds 
in the test set were calculated, and used to predict the IC50 value using the QSAR model. 
Their predicted IC50 values are given in (Table 7). The predicted IC50 ranged from 3.81E-
08 to 3.60E+118. The IC50 prediction of DB00014 yielded no result due to erroneous 
values for molecular descriptors. 
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Table 3 – List of compounds screened from DrugBank using the pharmacophore 
hypotheses with Fit value > 3.0000 while 4.0000 is the maximum fit value
DrugBank Id Fit Value 
DB00014 3.27232 
DB00175 3.46496 
DB00177 3.19198 
DB00178 3.33654 
DB00183 3.43056 
DB00197 3.28493 
DB00203 3.10751 
DB00206 3.64781 
DB00212 3.7264 
DB00213 3.18688 
DB00214 3.46049 
DB00220 3.49816 
DB00222 3.51832 
DB00224 3.40386 
DB00225 3.18938 
DB00227 3.43461 
DB00243 3.30593 
DB00251 3.16351 
DB00261 3.51503 
DB00274 3.28047 
DB00278 3.2984 
DB00287 3.46781 
DB00309 3.0552 
DB00317 3.42308 
DB00320 3.23793 
DB00337 3.14506 
DB00342 3.30076 
DB00346 3.5007 
DB00364 3.13604 
DB00372 3.00899 
DB00385 3.59763 
DB00391 3.1136 
DB00418 3.53516 
DB00438 3.39788 
DB00439 3.43932 
DB00444 3.72331 
DB00445 3.52043 
DB00447 3.13514 
DB00451 3.03649 
DB00457 3.61199 
DB00471 3.14337 
DB00481 3.28989 
DB00492 3.41804 
DB00502 3.53637 
DB00527 3.10779 
DB00528 3.48444 
DB00541 3.02446 
DB00549 3.35503 
DB00559 3.43289 
DB00562 3.13831 
DB00587 3.08904 
DB00590 3.45275 
DB00596 3.71368 
DB00607 3.12751 
DB00619 3.36395 
DB00622 3.51747 
DB00644 3.2535 
DB00646 3.45604 
DB00661 3.04429 
DB00680 3.02602 
DB00682 3.24277 
DB00688 3.21531 
DB00691 3.29817 
DB00694 3.53351 
DB00696 3.11765 
DB00705 3.32843 
DB00718 3.16567 
DB00732 3.31856 
DB00762 3.36274 
DB00767 3.18482 
DB00770 3.61628 
DB00773 3.81884 
DB00775 3.03273 
DB00796 3.01736 
DB00802 3.13447 
DB00803 3.45996 
DB00807 3.38792 
DB00826 3.32063 
DB00836 3.62363 
DB00862 3.36219 
DB00881 3.23329 
DB00882 3.57965 
DB00901 3.41364 
DB00905 3.42762 
DB00910 3.29055 
DB00912 3.31178 
DB00914 3.1722 
DB00929 3.15192 
DB00932 3.64571 
DB00938 3.20881 
DB00948 3.47897 
DB00950 3.41225 
DB00973 3.03287 
DB00976 3.16518 
DB00983 3.29732 
DB00997 3.60916 
DB01016 3.12595 
DB01029 3.3036 
DB01039 3.60824 
DB01046 3.38459 
DB01067 3.00265 
DB01070 3.45902 
DB01072 3.32943 
DB01083 3.5145 
DB01088 3.30871 
DB01089 3.42489 
DB01095 3.15418 
DB01098 3.17076 
DB01101 3.35517 
DB01118 3.36213 
DB01128 3.07768 
DB01130 3.43601 
DB01134 3.02213 
DB01135 3.15511 
DB01136 3.62998 
DB01138 3.30599 
DB01148 3.28163 
DB01149 3.22884 
DB01160 3.38237 
DB01162 3.5385 
DB01167 3.06741 
DB01177 3.63591 
DB01180 3.24226 
DB01200 3.01903 
DB01226 3.2906 
DB01248 3.34789 
DB01249 3.66409 
DB01251 3.53834 
DB01254 3.11323 
DB01256 3.44962 
DB01258 3.89234 
DB01263 3.26096 
DB01264 3.28708 
DB01274 3.20436 
DB01287 3.50898 
DB01295 3.22549 
DB01319 3.25027 
DB01321 3.22061 
DB01324 3.25065 
DB01326 3.58794 
DB01329 3.63602 
DB01332 3.2691 
DB01340 3.73321 
DB01342 3.35525 
DB01347 3.6452 
DB01348 3.09485 
DB01349 3.41247 
DB01361 3.07902 
DB01362 3.00244 
DB01388 3.3253 
DB01396 3.29558 
DB01410 3.19545 
DB01411 3.15169 
DB01416 3.33816 
DB01419 3.49755 
DB01425 3.52443 
DB01459 3.22367 
DB01462 3.29154 
DB01464 3.37844 
DB01487 3.45446 
DB01505 3.19056 
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DB01523 3.04914 
DB01570 3.25807 
DB01578 3.04856 
DB01601 3.50396 
DB01602 3.61448 
DB01604 3.13541 
DB01612 3.77316 
DB01627 3.52113 
DB01635 3.15009 
DB01660 3.41923 
DB01683 3.27805 
DB01691 3.2031 
DB01701 3.09992 
DB01709 3.26199 
DB01712 3.30574 
DB01713 3.23953 
DB01716 3.40471 
DB01737 3.62673 
DB01738 3.46857 
DB01745 3.20307 
DB01751 3.36796 
DB01755 3.80367 
DB01762 3.5282 
DB01812 3.2951 
DB01819 3.1474 
DB01829 3.24601 
DB01839 3.10125 
DB01842 3.03094 
DB01858 3.29419 
DB01864 3.40026 
DB01871 3.36834 
DB01872 3.02879 
DB01883 3.27621 
DB01891 3.46002 
DB01892 3.24711 
DB01914 3.28104 
DB01920 3.64399 
DB01922 3.12406 
DB01940 3.60919 
DB01965 3.0002 
DB01979 3.27231 
DB01991 3.15187 
DB02008 3.10181 
DB02017 3.18798 
DB02034 3.3265 
DB02041 3.10219 
DB02046 3.29579 
DB02056 3.1904 
DB02057 3.59205 
DB02062 3.12782 
DB02065 3.30082 
DB02071 3.0205 
DB02082 3.63258 
DB02095 3.39165 
DB02104 3.02905 
DB02115 3.20064 
DB02139 3.09955 
DB02140 3.2175 
DB02151 3.39826 
DB02169 3.33178 
DB02177 3.01818 
DB02210 3.16211 
DB02226 3.23326 
DB02229 3.21737 
DB02236 3.64682 
DB02237 3.11652 
DB02253 3.38631 
DB02255 3.20443 
DB02258 3.38961 
DB02263 3.47201 
DB02301 3.12812 
DB02333 3.51231 
DB02348 3.08521 
DB02349 3.00334 
DB02355 3.41628 
DB02370 3.63866 
DB02385 3.04737 
DB02395 3.16159 
DB02397 3.28321 
DB02423 3.12834 
DB02477 3.27328 
DB02484 3.41277 
DB02501 3.27513 
DB02545 3.4691 
DB02549 3.1614 
DB02550 3.05121 
DB02552 3.03335 
DB02555 3.35905 
DB02558 3.10085 
DB02565 3.04595 
DB02590 3.21659 
DB02597 3.52131 
DB02620 3.44382 
DB02632 3.1861 
DB02641 3.35132 
DB02663 3.30838 
DB02669 3.25089 
DB02696 3.29821 
DB02697 3.36541 
DB02703 3.165 
DB02706 3.45289 
DB02717 3.76578 
DB02721 3.10562 
DB02733 3.17963 
DB02777 3.3933 
DB02783 3.06979 
DB02787 3.1553 
DB02791 3.13738 
DB02804 3.22295 
DB02826 3.08476 
DB02848 3.49303 
DB02855 3.1331 
DB02858 3.06817 
DB02884 3.02029 
DB02892 3.13757 
DB02894 3.38135 
DB02907 3.29678 
DB02922 3.16342 
DB02932 3.07768 
DB02937 3.1044 
DB02946 3.443 
DB02975 3.5582 
DB02979 3.69251 
DB02993 3.42749 
DB03018 3.23333 
DB03029 3.10897 
DB03031 3.03559 
DB03053 3.24762 
DB03070 3.20834 
DB03077 3.44258 
DB03090 3.66922 
DB03103 3.46639 
DB03110 3.37712 
DB03133 3.65706 
DB03178 3.31986 
DB03189 3.32561 
DB03202 3.0995 
DB03240 3.35352 
DB03249 3.11133 
DB03300 3.36748 
DB03309 3.46019 
DB03319 3.56888 
DB03321 3.30974 
DB03336 3.25273 
DB03338 3.03826 
DB03343 3.21154 
DB03344 3.00026 
DB03359 3.21412 
DB03367 3.09658 
DB03382 3.30717 
DB03383 3.05495 
DB03393 3.32487 
DB03431 3.22121 
DB03434 3.37266 
DB03440 3.01773 
DB03446 3.02565 
DB03450 3.5249 
DB03459 3.4437 
DB03520 3.43233 
DB03537 3.20394 
DB03541 3.12176 
DB03550 3.26701 
DB03554 3.23361 
DB03556 3.38043 
DB03564 3.40158 
DB03573 3.27897 
DB03618 3.15675 
DB03629 3.20871 
DB03648 3.06799 
DB03673 3.16483 
DB03691 3.22832 
DB03692 3.37437 
DB03696 3.10655 
DB03708 3.41382 
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DB03730 3.1459 
DB03732 3.32688 
DB03735 3.21408 
DB03741 3.53202 
DB03744 3.36611 
DB03754 3.41443 
DB03767 3.4588 
DB03785 3.48979 
DB03793 3.20469 
DB03796 3.13682 
DB03814 3.52181 
DB03819 3.20061 
DB03830 3.32126 
DB03837 3.42291 
DB03855 3.45094 
DB03862 3.26126 
DB03866 3.3285 
DB03870 3.39905 
DB03878 3.07585 
DB03880 3.38237 
DB03890 3.01436 
DB03906 3.30576 
DB03919 3.29621 
DB03934 3.20265 
DB03943 3.30424 
DB03944 3.34285 
DB03971 3.49458 
DB03984 3.16249 
DB03991 3.35361 
DB03995 3.10207 
DB04012 3.4654 
DB04015 3.14791 
DB04036 3.01542 
DB04049 3.05244 
DB04075 3.44713 
DB04084 3.44516 
DB04092 3.43712 
DB04093 3.49894 
DB04133 3.01139 
DB04139 3.32542 
DB04140 3.4541 
DB04145 3.49873 
DB04156 3.44504 
DB04179 3.23004 
DB04187 3.40518 
DB04189 3.16964 
DB04200 3.36304 
DB04219 3.71055 
DB04231 3.2196 
DB04232 3.64386 
DB04234 3.18414 
DB04242 3.36753 
DB04261 3.2799 
DB04270 3.01639 
DB04276 3.32066 
DB04299 3.49912 
DB04310 3.01513 
DB04317 3.25154 
DB04320 3.47032 
DB04369 3.29803 
DB04386 3.29139 
DB04416 3.07406 
DB04421 3.43362 
DB04425 3.06762 
DB04441 3.6035 
DB04485 3.29038 
DB04487 3.59815 
DB04497 3.31768 
DB04498 3.52406 
DB04501 3.49731 
DB04505 3.41539 
DB04517 3.21327 
DB04529 3.04636 
DB04534 3.51577 
DB04542 3.56679 
DB04553 3.28683 
DB04570 3.37709 
DB04572 3.01147 
DB04574 3.66919 
DB04579 3.15399 
DB04580 3.05703 
DB04590 3.39385 
DB04592 3.433 
DB04594 3.51932 
DB04595 3.59709 
DB04609 3.45001 
DB04619 3.27595 
DB04622 3.32661 
DB04624 3.19172 
DB04626 3.42554 
DB04632 3.36163 
DB04642 3.34443 
DB04643 3.14372 
DB04644 3.08905 
DB04645 3.6189 
DB04657 3.36982 
DB04658 3.09994 
DB04673 3.43867 
DB04674 3.42552 
DB04680 3.23778 
DB04693 3.15864 
DB04695 3.25592 
DB04732 3.42656 
DB04738 3.35933 
DB04739 3.12429 
DB04746 3.38446 
DB04751 3.27724 
DB04771 3.12344 
DB04773 3.38935 
DB04781 3.44767 
DB04789 3.31897 
DB06699 3.20471 
DB06717 3.26503 
DB06829 3.14483 
DB06835 3.44175 
DB06844 3.27958 
DB06846 3.10273 
DB06859 3.01745 
DB06886 3.31257 
DB06892 3.01101 
DB06909 3.24602 
DB06953 3.06518 
DB06959 3.31184 
DB06960 3.37555 
DB06961 3.09784 
DB06964 3.13945 
DB06969 3.29195 
DB06970 3.1788 
DB06974 3.53364 
DB06979 3.0599 
DB06986 3.01438 
DB06993 3.06086 
DB07041 3.25019 
DB07046 3.01165 
DB07056 3.5143 
DB07062 3.26934 
DB07066 3.24501 
DB07068 3.14562 
DB07089 3.26274 
DB07090 3.54121 
DB07093 3.30163 
DB07105 3.19883 
DB07111 3.11053 
DB07113 3.34901 
DB07160 3.42859 
DB07165 3.17255 
DB07169 3.04386 
DB07172 3.00759 
DB07177 3.27814 
DB07188 3.21676 
DB07209 3.13653 
DB07219 3.35444 
DB07221 3.1903 
DB07223 3.38504 
DB07224 3.3704 
DB07225 3.36386 
DB07231 3.38987 
DB07246 3.13994 
DB07249 3.12858 
DB07250 3.38841 
DB07251 3.07339 
DB07255 3.09591 
DB07264 3.50321 
DB07269 3.42965 
DB07272 3.24546 
DB07276 3.28224 
DB07278 3.35521 
DB07309 3.27338 
DB07321 3.2265 
DB07325 3.03097 
DB07333 3.55434 
DB07334 3.43394 
DB07341 3.43029 
DB07349 3.21973 
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DB07351 3.53153 
DB07359 3.34329 
DB07362 3.13228 
DB07369 3.13765 
DB07370 3.05719 
DB07377 3.16709 
DB07379 3.16904 
DB07394 3.13371 
DB07397 3.11832 
DB07403 3.46466 
DB07413 3.31096 
DB07416 3.45423 
DB07429 3.02571 
DB07432 3.61073 
DB07446 3.32011 
DB07448 3.2955 
DB07460 3.0708 
DB07471 3.26785 
DB07475 3.40246 
DB07520 3.22486 
DB07537 3.42026 
DB07541 3.36487 
DB07558 3.34264 
DB07571 3.22055 
DB07572 3.69494 
DB07574 3.02731 
DB07582 3.29136 
DB07583 3.31588 
DB07602 3.45365 
DB07608 3.03313 
DB07615 3.00809 
DB07624 3.16186 
DB07627 3.10493 
DB07630 3.38644 
DB07633 3.21023 
DB07640 3.11709 
DB07657 3.33817 
DB07659 3.45481 
DB07675 3.30853 
DB07691 3.43133 
DB07692 3.01429 
DB07713 3.11644 
DB07724 3.38255 
DB07735 3.4419 
DB07738 3.5011 
DB07740 3.07738 
DB07750 3.15467 
DB07760 3.08613 
DB07765 3.38477 
DB07769 3.01401 
DB07770 3.12738 
DB07771 3.0657 
DB07772 3.09071 
DB07778 3.4989 
DB07779 3.48662 
DB07780 3.44264 
DB07784 3.01295 
DB07786 3.14929 
DB07792 3.57357 
DB07793 3.59994 
DB07800 3.24832 
DB07801 3.48707 
DB07804 3.08712 
DB07826 3.05045 
DB07827 3.05965 
DB07831 3.30738 
DB07832 3.55494 
DB07836 3.31347 
DB07839 3.33848 
DB07841 3.47019 
DB07844 3.18774 
DB07845 3.10007 
DB07846 3.15458 
DB07847 3.09737 
DB07848 3.3106 
DB07853 3.15355 
DB07861 3.08314 
DB07870 3.01414 
DB07875 3.03979 
DB07878 3.15234 
DB07881 3.53875 
DB07895 3.34934 
DB07898 3.5006 
DB07916 3.53539 
DB07926 3.33305 
DB07934 3.09244 
DB07936 3.6422 
DB07943 3.29641 
DB07946 3.19846 
DB07947 3.30277 
DB07962 3.04874 
DB07964 3.17217 
DB07967 3.3019 
DB07970 3.23301 
DB07974 3.32503 
DB07981 3.68001 
DB07982 3.0002 
DB07984 3.49608 
DB07988 3.08558 
DB07995 3.02247 
DB08001 3.07903 
DB08005 3.3147 
DB08009 3.50025 
DB08013 3.42261 
DB08014 3.32433 
DB08026 3.2574 
DB08078 3.17402 
DB08081 3.19259 
DB08086 3.27663 
DB08090 3.26292 
DB08105 3.17016 
DB08116 3.58996 
DB08118 3.20655 
DB08143 3.37454 
DB08147 3.28084 
DB08152 3.00496 
DB08154 3.47616 
DB08163 3.01833 
DB08169 3.3956 
DB08170 3.39782 
DB08173 3.11152 
DB08174 3.17037 
DB08177 3.17126 
DB08180 3.32813 
DB08185 3.39356 
DB08195 3.37956 
DB08221 3.22217 
DB08223 3.48597 
DB08226 3.37374 
DB08229 3.11298 
DB08240 3.15195 
DB08266 3.3126 
DB08275 3.13276 
DB08278 3.00038 
DB08282 3.02352 
DB08302 3.02876 
DB08310 3.05005 
DB08322 3.49423 
DB08324 3.06359 
DB08325 3.11189 
DB08341 3.05948 
DB08342 3.27843 
DB08344 3.43494 
DB08349 3.37915 
DB08350 3.11552 
DB08354 3.03027 
DB08366 3.39804 
DB08375 3.26791 
DB08376 3.36066 
DB08379 3.13324 
DB08387 3.32327 
DB08388 3.28485 
DB08403 3.10851 
DB08404 3.56304 
DB08407 3.17371 
DB08420 3.29087 
DB08429 3.17177 
DB08435 3.30676 
DB08437 3.31201 
DB08438 3.06511 
DB08444 3.5952 
DB08446 3.42654 
DB08457 3.46551 
DB08458 3.1417 
DB08459 3.54916 
DB08460 3.59298 
DB08463 3.0894 
DB08464 3.25917 
DB08465 3.50273 
DB08471 3.304 
DB08477 3.17603 
DB08481 3.39578 
DB08482 3.22652 
DB08483 3.15879 
37 
 
DB08487 3.15312 
DB08489 3.17874 
DB08490 3.03529 
DB08499 3.27014 
DB08502 3.00108 
DB08505 3.07571 
DB08526 3.35635 
DB08556 3.2513 
DB08582 3.08876 
DB08585 3.11964 
DB08586 3.11073 
DB08590 3.68935 
DB08614 3.05093 
DB08622 3.41244 
DB08633 3.34726 
DB08640 3.41984 
DB08643 3.29804 
DB08664 3.14168 
DB08669 3.13622 
DB08670 3.60572 
DB08690 3.10672 
DB08704 3.54552 
DB08706 3.08596 
DB08710 3.19863 
DB08719 3.01329 
DB08720 3.02005 
DB08721 3.42443 
DB08722 3.26748 
DB08727 3.2072 
DB08732 3.09532 
DB08733 3.69927 
DB08749 3.5617 
DB08755 3.47593 
DB08762 3.36458 
DB08772 3.71016 
DB08775 3.12828 
DB08810 3.64242 
DB08811 3.52842 
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Table 4 – Training Set compounds of QSAR model development with activity (IC50) and 
molecular descriptor data (Sv, Mv, Me, Mp, nBt, nCIC, Hy, MLogP, ALogP) 
Compound Id log IC50 Sv Mv Me Mp nBT nCIC Hy MLogP ALogP 
CHEMBL51698 1.176091 38.19 0.67 1.01 0.7 60 4 0.811 3.668 3.934 
CHEMBL51699 1.968483 38.19 0.67 1.01 0.7 60 4 0.811 3.668 3.934 
CHEMBL57146 1.50515 40.5 0.58 1 0.61 71 2 0.192 3.398 4.549 
CHEMBL58925 0 45.58 0.57 0.99 0.61 81 2 0.763 2.503 4.824 
CHEMBL73841 0.838849 38.91 0.65 1.02 0.67 63 4 0.162 4.289 4.235 
CHEMBL115852 1.755875 37.31 0.62 1.01 0.65 62 3 0.222 2.494 1.956 
CHEMBL117978 0.69897 34.22 0.63 1.03 0.65 56 3 0.27 2.447 1.435 
CHEMBL118450 1.672098 37.42 0.62 1.02 0.65 62 3 0.235 2.866 2.162 
CHEMBL119657 1.934498 35.11 0.62 1.01 0.64 59 3 0.257 1.031 1.146 
CHEMBL130093 -0.3098 39.31 0.66 1.02 0.68 63 4 0.801 3.866 4.144 
CHEMBL133746 1.120574 38.83 0.66 1.02 0.68 63 5 -0.355 3.936 4.909 
CHEMBL177969 1.69897 36.63 0.61 1.02 0.64 61 2 0.208 3.759 3.92 
CHEMBL179519 1.176091 36.46 0.66 1 0.72 59 5 -0.329 3.857 4.513 
CHEMBL180209 0 38.77 0.64 1 0.69 65 5 -0.341 3.403 4.598 
CHEMBL182327 1.531479 27.39 0.67 1.02 0.73 44 4 -0.26 3.925 4.574 
CHEMBL182349 1.612784 38.76 0.63 1 0.68 65 4 0.239 3.097 4.406 
CHEMBL183449 1.845098 28.19 0.64 1 0.68 47 4 -0.342 3.809 4.329 
CHEMBL183558 0.845098 38.17 0.64 1 0.69 64 5 0.239 3.097 4.17 
CHEMBL183585 1.875061 37.18 0.65 1 0.69 61 5 0.177 3.011 4.186 
CHEMBL183654 1.69897 26.57 0.65 1 0.71 44 4 -0.31 3.035 3.91 
CHEMBL183764 1.079181 36.37 0.67 1.01 0.72 58 5 0.239 3.143 4.431 
CHEMBL183777 1.792392 27.28 0.67 1 0.73 44 4 -0.284 3.54 4.369 
CHEMBL191302 1.431364 24.32 0.66 1.04 0.7 38 2 -0.198 3.345 4.057 
CHEMBL194084 1.255273 40.59 0.6 1.01 0.64 72 5 -0.334 4.547 5.055 
CHEMBL194422 1.230449 24.81 0.62 1.04 0.66 43 4 -0.198 3.218 4.473 
CHEMBL194788 0 38.77 0.64 1 0.69 65 5 -0.341 3.403 4.598 
CHEMBL196523 1.278754 39.17 0.59 0.99 0.64 70 5 -0.361 3.262 3.438 
CHEMBL198302 0.531479 37.9 0.6 1.02 0.64 67 5 -0.292 3.367 3.573 
CHEMBL199570 0.278754 30.03 0.65 1.04 0.69 48 3 0.318 3.823 4.662 
CHEMBL199912 0.041393 34.91 0.63 1.03 0.69 57 3 -0.671 4.182 5.076 
CHEMBL200176 0 35.23 0.65 1.03 0.69 57 4 -0.712 4.601 4.595 
CHEMBL200503 0.113943 32.71 0.64 1.02 0.68 53 3 -0.302 4.638 4.555 
CHEMBL200664 0.623249 31.72 0.65 1.03 0.7 51 3 -0.234 3.749 4.21 
CHEMBL200864 0.623249 31.72 0.65 1.03 0.7 51 3 0.33 3.749 4.263 
CHEMBL200913 1.029384 27.52 0.66 1.03 0.7 44 3 -0.277 4.459 4.493 
CHEMBL210279 0.790988 32.11 0.66 1.04 0.7 52 4 0.342 4.195 3.246 
CHEMBL211896 1.740363 28.52 0.66 1.03 0.71 45 3 -0.722 4.606 4.936 
CHEMBL291322 1.462398 37.71 0.66 1.02 0.68 60 4 0.82 3.668 3.681 
CHEMBL291976 1.851258 34.81 0.61 1 0.64 59 3 1.595 2.068 2.586 
CHEMBL332885 1.579784 35.11 0.62 1.01 0.64 59 3 0.257 1.031 0.854 
CHEMBL333710 0.255273 37.23 0.66 1.03 0.68 60 5 0.191 3.738 4.704 
CHEMBL336071 1.462398 27.39 0.67 1.02 0.73 44 4 -0.26 3.925 4.574 
CHEMBL362216 0.69897 38.28 0.63 1.01 0.68 65 5 -0.31 2.768 4.179 
CHEMBL366022 1 27.52 0.66 1.03 0.7 44 3 -0.277 4.459 4.493 
CHEMBL369557 -0.08619 34.91 0.63 1.03 0.69 57 3 -0.265 4.182 5.082 
CHEMBL370107 1.544068 31.12 0.65 1.03 0.69 50 3 -0.288 4.423 4.224 
CHEMBL371754 -1.09691 34.31 0.65 1.03 0.7 56 4 -0.265 4.182 4.495 
CHEMBL372156 1.886491 28.52 0.66 1.03 0.71 45 3 -0.722 4.606 4.936 
CHEMBL379089 0 32.11 0.64 1.03 0.68 52 3 0.96 4.041 4.345 
CHEMBL379758 0.672098 29.12 0.65 1.03 0.69 47 3 -0.294 4.682 4.823 
CHEMBL382060 -0.04576 33.71 0.65 1.03 0.7 55 4 -0.233 4.413 3.782 
CHEMBL383826 0.60206 40.48 0.61 1 0.65 68 3 0.206 2.403 2.644 
CHEMBL384207 1.880814 37.31 0.65 1.02 0.68 60 4 0.177 3.417 3.491 
CHEMBL406322 0.69897 37.93 0.62 1.03 0.64 63 3 0.877 2.127 1.616 
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QSAR model to predict IC50 value of potential inhibitors of gamma secretase from 
DrugBank 
logIC50 = 5.333468493034E+001 + 9.441980133615E–002*Sv 
 + 1.615431581663E+001*Mv + – 4.127786888796E+001*Me 
 + –2.451283848884E+001*Mp + –1.253675687200E–001*nBT 
 + 3.276417714217E–002*nCIC + –1.388896872996E–001*Hy 
 + 4.968101794863E–002*MLOGP + –1.111794822900E–001*ALOGP 
The following table serves to give a brief account of the various terms in the QSAR model 
developed to predict IC50. 
Table 5 - Molecular descriptors used in QSAR model along with its coefficient and input 
data range 
Descriptor Explanation Range Coefficient 
Sv sum of atomic van der Waals volumes 24.320 – 45.580 9.441980133615E–002 
Mv mean atomic van der Waals volume 00.570 – 00.670 1.615431581663E+001 
Me mean atomic Sanderson electronegativity 00.990 – 01.040 –4.127786888796E+001 
Mp mean atomic polarizability 00.610 – 00.730 –2.451283848884E+001 
nBT number of bonds 38.000 – 81.000 –1.253675687200E–001 
nCIC number of rings 02.000 – 05.000 3.276417714217E–002 
Hy hydrophilic factor -00.722 –  01.595 –1.388896872996E–001 
MLOGP Moriguchi octanol-water partition coeffecient 01.031 – 04.682 4.968101794863E–002 
ALOGP Ghose-Crippen octanol-water partition coeffecient 00.854 – 05.082 –1.111794822900E–001 
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Figure 3 - Plot of Actual activity data (log IC50) vs Predicted activity data (log IC50) 
Table 6 - Validation of QSAR model. Actual activity data (log IC50) and Predicted Activity 
data (log IC50)
Compound Id Actual IC50 Predicted IC50 
CHEMBL51698 1.18       1.16 
CHEMBL51699 1.97       1.16 
CHEMBL57146 1.51       1.10 
CHEMBL58925 0.00       0.42 
CHEMBL73841 0.84       0.93 
CHEMBL115852 1.76       1.45 
CHEMBL117978 0.70       1.30 
CHEMBL118450 1.67       1.04 
CHEMBL119657 1.93       1.88 
CHEMBL130093 -0.31       0.79 
CHEMBL133746 1.12       0.86 
CHEMBL177969 1.70       1.00 
CHEMBL179519 1.18       1.01 
CHEMBL180209 0.00       0.86 
CHEMBL182327 1.53       1.08 
CHEMBL182349 1.61       0.84 
CHEMBL183449 1.85       2.38 
CHEMBL183558 0.85       0.88 
CHEMBL183585 1.88       1.33 
CHEMBL183654 1.70       2.04 
CHEMBL183764 1.08       0.78 
CHEMBL183777 1.79       1.91 
CHEMBL191302 1.43       1.25 
CHEMBL194084 1.26       0.33 
CHEMBL194422 1.23       1.02 
CHEMBL194788 0.00       0.86 
CHEMBL196523 1.28       1.23 
CHEMBL198302 0.53       0.39 
CHEMBL199570 0.28       0.54 
CHEMBL199912 0.04       0.07 
CHEMBL200176 0.00       0.53 
CHEMBL200503 0.11       1.21 
CHEMBL200664 0.62       0.61 
CHEMBL200864 0.62       0.53 
CHEMBL200913 1.03       1.26 
CHEMBL210279 0.79       0.35 
CHEMBL211896 1.74       1.01 
CHEMBL291322 1.46       1.05 
CHEMBL291976 1.85       1.80 
CHEMBL332885 1.58       1.91 
CHEMBL333710 0.26       0.60 
CHEMBL336071 1.46       1.08 
CHEMBL362216 0.70       0.50 
CHEMBL366022 1.00       1.26 
CHEMBL369557 -0.09       0.01 
CHEMBL370107 1.54       0.96 
CHEMBL371754 -1.10       0.25 
CHEMBL372156 1.89       1.01 
CHEMBL379089 0.00       0.68 
CHEMBL379758 0.67       1.10 
CHEMBL382060 -0.05       0.41 
CHEMBL383826 0.60       1.17 
CHEMBL384207 1.88       0.95 
CHEMBL406322 0.70       0.73 
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Table 7 – Predicted IC50 values of the hits of pharmacophore screen of DrugBank 
compounds
DrugBank 
Id 
Predicted IC50 
DB02348 3.81E-08 
DB00732 1.14E-06 
DB00976 0.000311711 
DB00337 0.000535658 
DB01321 0.001612038 
DB02777 0.004394264 
DB01167 0.005202091 
DB00541 0.005233743 
DB01751 0.009622836 
DB01263 0.015164695 
DB01180 0.026539552 
DB02922 0.036372022 
DB00206 0.054918572 
DB00492 0.077143903 
DB04674 0.090207227 
DB01410 0.090997384 
DB01419 0.097180046 
DB01089 0.114075128 
DB02169 0.128672916 
DB00528 0.130116387 
DB01892 0.131788053 
DB01083 0.146228089 
DB07692 0.169452007 
DB07169 0.187343009 
DB01256 0.203074233 
DB00251 0.208713409 
DB01118 0.235493837 
DB00762 0.244249327 
DB02423 0.275189756 
DB02975 0.329850735 
DB00932 0.386193534 
DB02545 0.469168469 
DB01388 0.577240369 
DB01459 0.662676154 
DB07321 0.716987422 
DB03031 0.730506228 
DB01396 0.75426413 
DB00444 0.755936862 
DB03696 0.897846467 
DB00661 0.916346672 
DB00471 0.926668223 
DB01130 0.956238307 
DB00549 1.061458814 
DB08266 1.111649142 
DB01134 1.114938101 
DB06717 1.223170661 
DB08195 1.550482562 
DB01149 1.599870221 
DB01248 1.813602601 
DB00862 1.931435479 
DB06953 2.038262796 
DB07870 2.137557657 
DB01712 2.237392688 
DB08772 2.305665711 
DB08721 2.450858749 
DB00559 2.52673191 
DB00203 2.545069012 
DB07847 2.681155896 
DB00773 2.91742236 
DB07394 2.971823372 
DB00213 3.08640754 
DB07249 3.176551166 
DB04673 3.258753317 
DB01070 3.366556309 
DB01148 3.603814182 
DB08446 3.673846444 
DB01347 3.690095726 
DB08177 3.786500964 
DB07369 3.923531979 
DB02177 4.008961192 
DB07278 4.015508643 
DB07359 4.036080707 
DB00596 4.12517379 
DB07844 4.150280444 
DB08013 4.214840332 
DB00767 4.232942434 
DB00802 4.37897904 
DB08477 4.387232583 
DB00836 4.433389531 
DB00317 4.462990884 
DB08459 4.782383387 
DB07675 4.801973912 
DB08722 4.803108446 
DB00696 4.835972695 
DB08483 4.90981081 
DB01251 4.923074914 
DB07093 5.027065633 
DB03837 5.232905149 
DB02721 5.383614999 
DB01200 5.424874924 
DB08344 5.589559992 
DB02139 5.671880056 
DB00342 5.755347538 
DB08457 5.761958253 
DB00372 5.834282601 
DB08811 6.142314866 
DB06970 6.143585093 
DB00451 6.151493595 
DB04609 6.334569825 
DB01039 6.339743437 
DB00688 6.498383105 
DB03520 6.522469786 
DB00680 6.611450381 
DB01462 6.858932275 
DB08481 6.98256853 
DB07334 7.050592035 
DB00227 7.230824685 
DB08387 7.598323948 
DB00691 7.618034224 
DB08154 7.62023424 
DB00320 7.681857778 
DB03944 7.72808924 
DB08471 7.972992125 
DB07403 8.154936986 
DB01138 8.283567678 
DB03336 8.374951775 
DB07827 8.623147018 
DB02804 8.837301517 
DB01088 9.536999584 
DB08014 10.18023054 
DB07836 10.41213603 
DB02703 10.60927423 
DB01523 10.79536273 
DB00882 10.85080715 
DB07349 11.09156596 
DB00481 11.24452046 
DB06974 11.86151121 
DB07219 11.89067029 
DB00197 12.02332796 
DB07724 12.37127699 
DB07769 12.53901026 
DB01348 13.04481577 
DB01128 13.05211767 
DB02932 13.05211767 
DB00718 13.22966021 
DB07800 13.7824937 
DB03554 14.04092284 
DB01324 14.15607988 
DB00309 14.20273869 
DB04738 14.24531646 
DB04270 14.27527693 
DB00385 14.44730607 
DB01601 14.49037116 
DB08556 14.68449556 
DB08152 14.78550344 
DB01464 14.80037714 
DB08719 14.86436866 
DB07471 15.04866161 
DB00901 15.60140331 
DB04232 15.67497266 
DB08502 15.72455769 
DB08582 16.09107524 
DB08585 16.09107524 
DB08633 16.67259795 
DB03890 16.70290996 
DB03556 16.71159972 
DB07846 17.54329901 
DB08143 17.54502312 
DB07936 18.24600405 
DB07056 19.07653729 
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DB07250 19.22667546 
DB01072 19.28745327 
DB07309 19.50751145 
DB06892 20.22436475 
DB00622 20.42667256 
DB00274 20.43166373 
DB02226 20.74486169 
DB02550 22.0780343 
DB08278 22.426288 
DB07333 22.71186878 
DB08727 23.19140953 
DB08690 23.55496864 
DB02253 23.91832438 
DB07962 24.15394943 
DB04574 24.24609981 
DB01029 24.54498881 
DB08458 25.17730444 
DB00224 25.44304671 
DB02791 25.95292883 
DB06844 26.04699153 
DB08282 26.40537153 
DB08755 27.23316175 
DB07804 27.58996761 
DB00590 27.59213078 
DB04595 27.62018058 
DB01411 28.17649928 
DB08221 28.72993131 
DB02894 29.79939876 
DB07974 30.32384298 
DB08226 30.41643688 
DB00287 30.81642505 
DB04317 31.51791371 
DB07255 31.60122012 
DB00950 32.69915131 
DB07640 32.78124856 
DB08490 33.37865711 
DB07691 34.00457028 
DB02706 34.29146068 
DB04739 34.79638272 
DB00243 35.32849204 
DB08444 35.33570142 
DB00973 35.49738772 
DB08349 36.83138578 
DB01342 36.9897858 
DB00587 37.15874359 
DB07770 37.19607425 
DB00912 38.61783112 
DB07778 39.07279091 
DB07967 39.95642035 
DB08379 40.70629863 
DB08147 40.87515853 
DB01570 41.04681715 
DB07826 41.12785243 
DB07848 41.19177745 
DB00948 41.72430157 
DB07981 41.97247274 
DB07984 41.97247274 
DB01329 42.13299469 
DB00619 43.91280048 
DB02848 44.66188467 
DB08310 45.74398685 
DB07276 46.51766058 
DB07541 46.74678646 
DB04012 47.52140224 
DB08376 47.9562035 
DB02858 48.13094039 
DB00222 48.13921289 
DB07583 48.19615105 
DB08720 49.05134228 
DB02008 49.43699948 
DB00502 49.52883072 
DB01340 51.64215073 
DB00562 52.96611132 
DB07188 55.25928939 
DB00607 56.7945971 
DB04140 57.16452076 
DB00212 57.49420562 
DB08590 57.67619247 
DB01691 57.74990297 
DB03984 58.17947578 
DB07062 58.91035754 
DB08710 59.0263144 
DB00261 60.43684855 
DB04505 61.10735255 
DB02071 63.60350033 
DB07090 65.73976713 
DB02946 66.57790175 
DB04642 66.7405177 
DB07429 67.12810397 
DB01349 67.18304893 
DB07574 68.00611705 
DB00881 69.24225124 
DB00220 71.47864857 
DB07964 73.27199306 
DB07251 74.46867861 
DB00177 75.60274692 
DB08174 78.34161895 
DB07878 78.76157103 
DB08350 78.77990504 
DB08388 79.36483516 
DB00929 79.57301041 
DB08706 84.93159871 
DB01016 86.58658764 
DB04693 88.01733772 
DB00178 89.06213468 
DB00527 91.66379965 
DB00796 91.84092942 
DB07068 95.55264233 
DB08614 95.71894318 
DB08622 95.71894318 
DB01046 97.41320828 
DB08302 100.641473 
DB08078 101.2015464 
DB01264 105.9903972 
DB04416 110.1857888 
DB08173 111.7348277 
DB08435 113.6742946 
DB03866 119.3144066 
DB07947 120.5958566 
DB07624 122.7609298 
DB07832 123.255345 
DB07875 128.1088405 
DB07582 130.3728379 
DB07841 133.5920292 
DB03367 136.1975616 
DB00682 137.9838223 
DB08341 139.9408802 
DB08086 140.4423279 
DB04643 142.880314 
DB08749 144.4133736 
DB02258 145.570467 
DB02140 148.2422977 
DB08487 152.7575766 
DB00910 153.1173899 
DB07223 154.2000716 
DB07988 154.3862726 
DB01871 154.9262242 
DB06961 155.3522808 
DB04644 155.412954 
DB04645 156.6111216 
DB08223 156.9200781 
DB07165 157.0444257 
DB06886 159.8542878 
DB04234 160.2565418 
DB04632 160.4122741 
DB07982 161.9992285 
DB00439 168.9949342 
DB01098 169.677065 
DB07416 170.3442087 
DB00775 171.2566738 
DB00705 179.2778369 
DB03785 183.2491536 
DB00457 183.722619 
DB07362 186.4105304 
DB07630 189.3272967 
DB01254 198.27068 
DB01505 198.4732809 
DB04746 199.4601831 
DB00438 208.6486923 
DB07446 209.1618455 
DB07943 209.8692913 
DB03383 210.8040978 
DB07995 215.4545106 
DB08324 224.4440867 
DB07839 226.3066801 
DB08664 227.3635251 
DB06829 227.6389824 
DB08460 231.7184559 
DB06846 232.6155366 
DB08429 234.0071243 
DB01162 234.5518056 
DB01701 241.2307994 
DB07738 241.3989021 
DB08180 250.8631445 
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DB03767 264.4079981 
DB04200 267.0730989 
DB06969 268.9406653 
DB01602 269.668359 
DB03878 281.1882788 
DB08499 282.1318282 
DB01326 284.6668605 
DB01858 285.9534691 
DB07460 291.9497477 
DB07177 329.6714838 
DB01295 356.0202432 
DB02549 361.6608731 
DB08001 363.8151866 
DB07735 363.8810707 
DB07784 371.5522982 
DB04369 373.306971 
DB06959 381.9726162 
DB07713 390.5724441 
DB07772 390.5724441 
DB03744 396.9262088 
DB07853 397.2935213 
DB03796 402.4330891 
DB07793 425.7246941 
DB01604 433.5249678 
DB07657 446.9978686 
DB04572 448.3758452 
DB01319 459.7327498 
DB06909 460.805867 
DB07615 464.0013879 
DB01745 465.5363892 
DB06964 469.1931748 
DB07572 478.1311267 
DB08526 485.0925619 
DB07861 498.9910201 
DB02669 506.323588 
DB01095 508.2611968 
DB08240 514.4301996 
DB04570 522.5824218 
DB08354 540.0646063 
DB07831 542.4471393 
DB07231 543.4852472 
DB08170 570.2867154 
DB08463 593.5113956 
DB08105 613.2776584 
DB01067 624.328784 
DB07750 634.5891503 
DB04695 636.6225541 
DB04534 760.7171982 
DB07520 773.1374578 
DB07786 798.6074522 
DB07172 839.8626588 
DB08118 847.5916728 
DB01136 861.900571 
DB07225 888.0008193 
DB03202 890.6274184 
DB07046 895.4470844 
DB08640 950.2436511 
DB08009 976.7401323 
DB07111 983.7956596 
DB03450 983.8869683 
DB01819 1006.325764 
DB07780 1037.084504 
DB01425 1080.166986 
DB08322 1147.622536 
DB04049 1157.613217 
DB07264 1188.577178 
DB08732 1197.779373 
DB07916 1246.458843 
DB08026 1258.816699 
DB02555 1292.74357 
DB07760 1293.232883 
DB04657 1414.266029 
DB08762 1417.326114 
DB01940 1521.981973 
DB06979 1541.644238 
DB03440 1635.661015 
DB07209 1679.137591 
DB08081 1721.804615 
DB08169 1736.351234 
DB08775 1741.458531 
DB04732 1747.173123 
DB04580 1774.818325 
DB07272 1776.563286 
DB00807 1813.413081 
DB04179 1833.323367 
DB00346 1899.679022 
DB08810 1923.110062 
DB07160 1953.563131 
DB03110 1976.296631 
DB03343 2108.265779 
DB07066 2109.00372 
DB08489 2134.203236 
DB07113 2173.392764 
DB07970 2186.707526 
DB07351 2205.425021 
DB06986 2224.341776 
DB06993 2260.510209 
DB02056 2339.274871 
DB04133 2352.804051 
DB03814 2377.678059 
DB07771 2388.339163 
DB07224 2394.685157 
DB00770 2405.636207 
DB01991 2406.031195 
DB08275 2411.259502 
DB07558 2517.084163 
DB04542 2538.580034 
DB07246 2597.008548 
DB07934 2642.942529 
DB03880 2695.329172 
DB08366 2712.810619 
DB08505 2714.792197 
DB03359 2719.413667 
DB07881 2745.110132 
DB04773 2754.144915 
DB08342 2774.808761 
DB03249 2782.390222 
DB02565 2829.382615 
DB03629 2854.745764 
DB07779 2927.762803 
DB03434 2929.364525 
DB02395 3186.941898 
DB02620 3239.146823 
DB08005 3325.930351 
DB02095 3339.031609 
DB01487 3450.826309 
DB08407 3487.387072 
DB01891 3819.647726 
DB04751 3947.388606 
DB01101 4016.007853 
DB04624 4065.830416 
DB08643 4065.890705 
DB00938 4409.613434 
DB07221 4454.15548 
DB08404 4612.893553 
DB01416 4671.329805 
DB08116 4718.625533 
DB02477 4916.975555 
DB04517 4992.319191 
DB04093 5174.284067 
DB07571 5414.09464 
DB01332 5484.139135 
DB06960 5567.337805 
DB02552 5681.282628 
DB03735 5704.410077 
DB00905 5816.222628 
DB01258 5947.64739 
DB00214 6252.160844 
DB07792 6553.022553 
DB04619 6643.717987 
DB07765 6645.612324 
DB00175 6808.899973 
DB07089 6884.316799 
DB04299 7400.736969 
DB08482 7566.687237 
DB08465 8175.047486 
DB03793 8292.801231 
DB08325 8737.264097 
DB00391 8823.326637 
DB07895 8900.748998 
DB04553 9494.723661 
DB07740 9585.688912 
DB02558 9785.968516 
DB07845 9892.074633 
DB02733 10262.35376 
DB04320 10915.41632 
DB01762 11162.14763 
DB06835 11539.12017 
DB07475 11553.88415 
DB03090 12079.63062 
DB06859 12331.57269 
DB00418 12614.14586 
DB02979 13443.69641 
DB07801 13587.64624 
44 
 
DB07413 13743.97802 
DB02826 14881.74113 
DB02263 14884.72318 
DB08229 15046.45379 
DB03103 16356.89987 
DB04680 18065.92501 
DB04592 18848.85804 
DB04310 19204.42782 
DB08185 19616.00924 
DB02333 20192.89741 
DB03029 20201.01146 
DB02597 20473.21013 
DB04501 20504.21444 
DB08437 21132.96316 
DB01578 22293.94153 
DB08586 22748.89607 
DB07537 23804.00609 
DB02104 24807.24658 
DB01612 25859.7386 
DB07325 27457.83637 
DB04242 27738.7725 
DB02115 27913.33601 
DB02855 28460.25827 
DB07448 29006.04531 
DB00694 29723.85962 
DB08438 29918.85376 
DB07926 30238.37614 
DB07633 30706.23877 
DB07397 32932.83197 
DB03309 33508.73812 
DB08375 34210.15966 
DB03573 35448.97692 
DB03691 35448.97692 
DB03692 35448.97692 
DB00447 35660.5266 
DB04485 39492.30877 
DB08420 42531.46759 
DB07269 45700.37589 
DB08464 46683.72154 
DB04145 49258.21455 
DB02046 49765.22333 
DB08733 54129.24078 
DB03077 54398.93747 
DB07608 56457.14511 
DB07898 57111.02633 
DB01737 57897.43825 
DB03178 59172.51202 
DB01627 67512.01671 
DB02062 75980.7839 
DB08670 77823.08096 
DB01920 77966.44695 
DB02632 77966.44695 
DB00826 81700.29935 
DB07370 83595.28553 
DB00983 85741.22702 
DB01274 85741.22702 
DB07627 86882.87684 
DB01709 102920.8671 
DB04590 103695.7638 
DB01177 106697.6618 
DB01635 109115.3673 
DB08090 118556.8244 
DB08669 126016.1721 
DB03919 150073.1451 
DB07432 158635.9683 
DB03446 167248.4945 
DB08403 183847.3344 
DB00183 188964.8394 
DB04075 194732.3898 
DB03708 209496.5094 
DB07041 212151.6545 
DB07602 224075.4437 
DB03319 227558.5416 
DB04771 252140.4824 
DB04386 259595.426 
DB02255 259776.1199 
DB03673 266858.5559 
DB03732 277498.0177 
DB03741 284275.197 
DB03382 306379.5726 
DB07379 306763.5896 
DB08704 337044.4817 
DB00445 343713.9126 
DB00997 343713.9126 
DB03550 344856.4635 
DB02783 350682.4707 
DB04594 369941.2246 
DB03541 374848.2613 
DB01883 381833.2465 
DB07341 391215.312 
DB03338 420733.9939 
DB03730 424531.269 
DB02993 459707.1295 
DB04092 491100.0022 
DB07946 552101.2589 
DB07659 561217.5787 
DB04421 566753.9966 
DB04579 610477.7331 
DB04622 689927.8822 
DB03819 691897.6283 
DB04487 694764.4511 
DB04015 777201.2776 
DB02301 787284.8102 
DB01965 819116.1731 
DB04781 834478.6733 
DB03053 852005.0717 
DB01683 891330.2667 
DB01872 1025121.84 
DB02696 1059316.23 
DB00278 1090636.513 
DB04139 1214614.071 
DB07377 1281175.975 
DB03830 1345439.326 
DB02236 1523451.425 
DB03459 1625062.118 
DB03240 1862937.374 
DB03018 1989201.54 
DB02034 2100725.338 
DB04441 2172473.197 
DB04187 2250674.109 
DB02884 2707459.306 
DB02355 2730567.986 
DB01660 2781364.561 
DB08163 3391956.214 
DB02057 3437149.437 
DB02210 3498403.568 
DB03133 3693962.436 
DB04084 3695356.725 
DB02590 3780356.965 
DB01362 3898714.844 
DB03564 4008827.711 
DB03648 4477664.397 
DB01713 4508732.679 
DB02641 4896376.956 
DB02907 6313241.99 
DB01842 6990995.439 
DB02041 8045178.219 
DB01979 8446697.143 
DB01812 8577475.012 
DB03431 8577475.012 
DB02892 9131600.757 
DB02151 9725572.673 
DB00646 10817056.5 
DB02663 12003052.5 
DB01829 21557341.64 
DB02484 22044316.88 
DB01716 26125077 
DB01738 29144402.8 
DB01864 42249103.2 
DB01839 45529833.76 
DB03991 46155768.4 
DB03870 60360464.4 
DB04036 61318536.69 
DB03070 66462085.47 
DB03537 80873494.34 
DB01249 84462343.7 
DB07105 106056323.8 
DB04261 110158016.2 
DB02229 115846503 
DB03862 141227827.1 
DB02370 152405217.8 
DB04789 165074615 
DB02017 166690307.7 
DB02385 204139685.5 
DB02065 206695425.6 
DB01755 312035374.3 
DB01914 588550115.4 
DB04658 703651348.5 
DB03618 1040030546 
DB03300 1144545329 
DB02697 1340252624 
DB02397 1838798601 
DB03344 2331013037 
DB02082 2475402019 
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DB03321 2552621120 
DB04497 2974157198 
DB03943 6281636668 
DB03855 6739900900 
DB00914 15074052275 
DB02501 17341202790 
DB04425 18066310608 
DB04189 27859532660 
DB02787 1.00E+11 
DB02349 1.28E+11 
DB04276 4.35E+11 
DB01922 2.91E+12 
DB02237 3.82E+12 
DB03754 7.86E+12 
DB02717 5.94E+13 
DB03971 1.53E+16 
DB04626 1.86E+16 
DB00225 2.16E+53 
DB00644 2.16E+53 
DB00803 2.16E+53 
DB01135 2.16E+53 
DB01160 2.16E+53 
DB01226 2.16E+53 
DB01287 2.16E+53 
DB01361 2.16E+53 
DB03393 2.16E+53 
DB03995 2.16E+53 
DB04156 2.16E+53 
DB04219 2.16E+53 
DB04498 2.16E+53 
DB04529 2.16E+53 
DB06699 2.16E+53 
DB03906 2.01E+110 
DB03934 4.36E+110 
DB03189 4.93E+112 
DB04231 6.48E+112 
DB00364 1.96E+115 
DB02937 3.60E+118 
DB00014  
  
No. of compounds with Predicted IC50 under 1nM  = 42 
No. of compounds with Predicted IC50 under 10nM  = 119 
No. of compounds with Predicted IC50 under 100nM = 272 
No. of compounds with Predicted IC50 under 1000nM = 394 
No. of compounds with Predicted IC50 under 10000nM = 498  
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4.4 Docking study 
4.4.1 Binding site definition 
The binding sites were defined using QsiteFinder. The binding site with Asp 385 
was identified. Its geometric co-ordinates were noted as x= -5, y=72, z=-14, X=11, Y= 86, 
Z=1. These define the box for binding analysis in the docking program.  
 
Figure 4 - Binding site with Asp 385 predicted using QsiteFinder on the CTF of presenilin 
(2KR6). The binding site’s surface is marked in purple, while Asp 385 is marked in cyan. 
4.4.2 Docking using SwissDock 
Docking was performed with SwissDock. The receptor was CTF of Presenilin 
2KR6 while the 498 compounds with predicted IC50 >=10000 nM, were the ligands used. 
The binding box was defined with the geometric co-ordinates predicted using QsiteFinder 
tool, x= -5, y=72, z=-14, X=11, Y= 86, Z=1. Docking study yielded 55 compounds with 
estimated free energy of binding lesser than -8.00 kcal/mol (Figure 5a & 5b). The range of 
estimated free energy of binding is  -12.39 kcal/mol to -5.20 kcal/mol. The attempt to 
perform docking studies failed for 51 compounds either due to complexity of the ligand 
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structure for the docking program or due to loss of data due to the crashing of docking 
program. 
 
DB02777 DB01263 DB00471 DB00206 
DB02549 DB02477 DB01167 DB08180 
DB08376 DB07349 DB01396 DB02169 
DB03031 DB00691 DB01258 DB00688 
DB08499 DB08585 DB00203 DB00549 
DB01329 DB07836 DB04542 DB01991 
Figure 5a – Hits of docking study and estimated free energy of binding screen ∆G 
<= -8.00 kcal/mol for the compounds with predicted IC50 <=10000nM 
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DB07780 DB07765 DB03336 DB00932 
DB01083 DB08810 DB00718 DB01254 
DB08342 DB06717 DB07264 DB00559 
DB07362 DB07394 DB01871 DB07165 
DB08721 DB01419 DB00177 DB08477 
DB08404 DB08762 DB00178 DB07974 
DB01319 DB04695 DB07947 DB00948 
DB01321 DB01411 DB00528 
Figure 5b – Hits of docking study and estimated free energy of binding screen, ∆G 
<= -8.00 kcal/mol for the compounds with predicted IC50 <=10000nM 
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Table 8 – Result of docking study showing estimated free energy of binding for the 
compounds with predicted IC50 <=10000nM 
DrugBank 
Id 
∆G 
(kcal/mol) 
DB02777 -12.39 
DB01263 -9.12 
DB00471 -8.92 
DB00206 -8.87 
DB02549 -8.86 
DB02477 -8.77 
DB01167 -8.60 
DB08180 -8.59 
DB08376 -8.53 
DB07349 -8.52 
DB01396 -8.45 
DB02169 -8.41 
DB03031 -8.41 
DB00691 -8.37 
DB01258 -8.36 
DB00688 -8.35 
DB08499 -8.35 
DB08585 -8.35 
DB00203 -8.33 
DB00549 -8.32 
DB01329 -8.31 
DB07836 -8.31 
DB04542 -8.30 
DB01991 -8.29 
DB07780 -8.28 
DB07765 -8.26 
DB03336 -8.25 
DB00932 -8.23 
DB01083 -8.21 
DB08810 -8.21 
DB00718 -8.20 
DB01254 -8.20 
DB08342 -8.20 
DB06717 -8.18 
DB07264 -8.17 
DB00559 -8.16 
DB07362 -8.15 
DB07394 -8.15 
DB01871 -8.14 
DB07165 -8.13 
DB08721 -8.13 
DB01419 -8.09 
DB00177 -8.08 
DB08477 -8.08 
DB08404 -8.07 
DB08762 -8.07 
DB00178 -8.06 
DB07974 -8.06 
DB01319 -8.04 
DB04695 -8.04 
DB07947 -8.04 
DB00948 -8.02 
DB01321 -8.02 
DB01411 -8.02 
DB00528 -8.01 
DB01067 -7.98 
DB07675 -7.97 
DB07870 -7.97 
DB03556 -7.95 
DB08490 -7.95 
DB08429 -7.93 
DB07844 -7.92 
DB04270 -7.91 
DB01095 -7.90 
DB07255 -7.90 
DB07982 -7.90 
DB00251 -7.89 
DB01332 -7.89 
DB04645 -7.89 
DB07630 -7.89 
DB07995 -7.89 
DB02620 -7.88 
DB07068 -7.87 
DB07251 -7.87 
DB06960 -7.86 
DB07875 -7.86 
DB03984 -7.85 
DB04570 -7.85 
DB04642 -7.85 
DB07624 -7.85 
DB08710 -7.84 
DB07861 -7.83 
DB02804 -7.82 
DB03343 -7.82 
DB07221 -7.82 
DB07881 -7.82 
DB00619 -7.81 
DB01149 -7.81 
DB03359 -7.81 
DB07916 -7.81 
DB00773 -7.80 
DB08026 -7.80 
DB08487 -7.80 
DB01251 -7.79 
DB02545 -7.79 
DB04517 -7.79 
DB07369 -7.79 
DB08174 -7.79 
DB08749 -7.79 
DB07583 -7.78 
DB01326 -7.77 
DB02669 -7.77 
DB06829 -7.76 
DB07111 -7.76 
DB08755 -7.76 
DB00243 -7.75 
DB01264 -7.75 
DB07231 -7.75 
DB00346 -7.74 
DB07460 -7.74 
DB00661 -7.73 
DB07062 -7.73 
DB07333 -7.72 
DB06892 -7.71 
DB04609 -7.70 
DB04673 -7.69 
DB06844 -7.69 
DB06993 -7.69 
DB07750 -7.69 
DB08463 -7.69 
DB01342 -7.68 
DB02706 -7.68 
DB06846 -7.68 
DB00912 -7.67 
DB01098 -7.67 
DB01940 -7.67 
DB04632 -7.67 
DB06886 -7.67 
DB07272 -7.67 
DB07582 -7.67 
DB01180 -7.66 
DB00342 -7.65 
DB00391 -7.65 
DB00938 -7.65 
DB07334 -7.65 
DB01016 -7.64 
DB01162 -7.64 
DB02056 -7.64 
DB02253 -7.64 
DB06969 -7.64 
DB07691 -7.64 
DB08014 -7.64 
DB08173 -7.64 
DB07089 -7.63 
DB07832 -7.62 
DB07988 -7.62 
DB08078 -7.62 
DB01088 -7.61 
DB03249 -7.61 
DB07278 -7.61 
DB03367 -7.60 
DB04644 -7.60 
DB08275 -7.60 
DB07804 -7.59 
DB07839 -7.59 
DB08143 -7.59 
DB08325 -7.59 
DB03837 -7.58 
DB06909 -7.58 
DB07209 -7.58 
DB07786 -7.58 
DB07845 -7.58 
DB08177 -7.58 
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DB08446 -7.58 
DB00451 -7.57 
DB01858 -7.57 
DB03785 -7.57 
DB04140 -7.57 
DB07351 -7.57 
DB07771 -7.57 
DB08116 -7.57 
DB08526 -7.57 
DB08722 -7.57 
DB03440 -7.56 
DB04133 -7.56 
DB08322 -7.56 
DB01029 -7.55 
DB07113 -7.55 
DB01745 -7.54 
DB00385 -7.53 
DB08341 -7.53 
DB08483 -7.53 
DB00950 -7.52 
DB07321 -7.52 
DB07769 -7.52 
DB08444 -7.52 
DB01349 -7.51 
DB03202 -7.51 
DB07169 -7.51 
DB07403 -7.51 
DB07571 -7.51 
DB08147 -7.51 
DB00444 -7.50 
DB03450 -7.50 
DB07967 -7.50 
DB08266 -7.50 
DB08349 -7.50 
DB08633 -7.50 
DB00796 -7.49 
DB01348 -7.49 
DB02848 -7.48 
DB07046 -7.47 
DB08590 -7.47 
DB00696 -7.46 
DB00770 -7.46 
DB01136 -7.46 
DB01324 -7.46 
DB07172 -7.46 
DB08152 -7.46 
DB08223 -7.46 
DB01347 -7.45 
DB03944 -7.45 
DB07853 -7.45 
DB07964 -7.45 
DB00607 -7.44 
DB01416 -7.44 
DB04739 -7.44 
DB06953 -7.44 
DB07558 -7.44 
DB08221 -7.44 
DB00481 -7.43 
DB00590 -7.43 
DB02558 -7.43 
DB07760 -7.43 
DB00562 -7.42 
DB01046 -7.42 
DB02071 -7.42 
DB07826 -7.42 
DB00622 -7.41 
DB07177 -7.41 
DB07740 -7.41 
DB07831 -7.41 
DB07848 -7.41 
DB06959 -7.40 
DB06974 -7.40 
DB07056 -7.40 
DB07936 -7.40 
DB08465 -7.40 
DB04751 -7.39 
DB08324 -7.39 
DB08727 -7.39 
DB08772 -7.39 
DB01751 -7.38 
DB07090 -7.38 
DB07219 -7.38 
DB08278 -7.38 
DB01295 -7.37 
DB07093 -7.37 
DB08481 -7.37 
DB00905 -7.36 
DB01138 -7.36 
DB01691 -7.36 
DB03767 -7.36 
DB00287 -7.35 
DB00901 -7.35 
DB07800 -7.35 
DB07895 -7.35 
DB08622 -7.35 
DB04234 -7.34 
DB07692 -7.34 
DB08505 -7.34 
DB00372 -7.33 
DB07223 -7.33 
DB07792 -7.33 
DB07970 -7.33 
DB08226 -7.33 
DB00541 -7.32 
DB04232 -7.32 
DB07246 -7.32 
DB07981 -7.32 
DB08706 -7.32 
DB01200 -7.31 
DB07359 -7.31 
DB07878 -7.31 
DB08719 -7.31 
DB00705 -7.30 
DB08388 -7.30 
DB08582 -7.30 
DB00802 -7.29 
DB01891 -7.29 
DB03890 -7.29 
DB07416 -7.29 
DB07784 -7.29 
DB08282 -7.29 
DB08344 -7.29 
DB00274 -7.28 
DB00836 -7.28 
DB04643 -7.28 
DB07541 -7.28 
DB08460 -7.27 
DB00762 -7.26 
DB00862 -7.26 
DB03744 -7.26 
DB08195 -7.26 
DB03796 -7.25 
DB04416 -7.25 
DB06970 -7.25 
DB07250 -7.25 
DB08154 -7.25 
DB01604 -7.23 
DB08664 -7.22 
DB08732 -7.22 
DB07224 -7.21 
DB07429 -7.21 
DB07640 -7.21 
DB08720 -7.21 
DB00457 -7.20 
DB02550 -7.20 
DB07225 -7.20 
DB00502 -7.19 
DB00881 -7.19 
DB00910 -7.19 
DB04049 -7.19 
DB04200 -7.19 
DB08169 -7.19 
DB08310 -7.19 
DB08471 -7.18 
DB01089 -7.17 
DB02932 -7.17 
DB04505 -7.17 
DB07847 -7.17 
DB08458 -7.17 
DB01118 -7.16 
DB01128 -7.16 
DB01462 -7.16 
DB07471 -7.16 
DB07249 -7.15 
DB07615 -7.15 
DB08387 -7.15 
DB04012 -7.14 
DB07572 -7.14 
DB08407 -7.14 
DB08457 -7.14 
DB08459 -7.14 
DB02565 -7.13 
DB06961 -7.13 
DB04624 -7.12 
DB07188 -7.12 
DB07827 -7.12 
DB08366 -7.12 
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DB08489 -7.12 
DB08556 -7.12 
DB08811 -7.12 
DB06979 -7.10 
DB00320 -7.09 
DB01388 -7.09 
DB03383 -7.09 
DB07779 -7.09 
DB00767 -7.08 
DB01039 -7.08 
DB01340 -7.08 
DB07962 -7.08 
DB01523 -7.07 
DB07738 -7.07 
DB07770 -7.07 
DB04574 -7.06 
DB08640 -7.06 
DB00317 -7.05 
DB03814 -7.05 
DB07713 -7.05 
DB00929 -7.04 
DB03878 -7.04 
DB08435 -7.04 
DB00682 -7.02 
DB06964 -7.02 
DB08482 -7.02 
DB07309 -7.01 
DB08118 -7.01 
DB01148 -7.00 
DB08354 -6.99 
DB00587 -6.98 
DB07735 -6.98 
DB07793 -6.98 
DB00680 -6.97 
DB02894 -6.97 
DB07943 -6.97 
DB08502 -6.97 
DB01459 -6.96 
DB04746 -6.96 
DB06986 -6.96 
DB08350 -6.92 
DB00527 -6.91 
DB07778 -6.91 
DB08614 -6.90 
DB00973 -6.89 
DB07066 -6.89 
DB07276 -6.89 
DB01570 -6.88 
DB08775 -6.87 
DB08081 -6.86 
DB01712 -6.85 
DB07846 -6.84 
DB00439 -6.83 
DB00882 -6.83 
DB07724 -6.83 
DB01101 -6.81 
DB01256 -6.79 
DB01464 -6.79 
DB03434 -6.79 
DB03735 -6.79 
DB01487 -6.78 
DB01425 -6.77 
DB01602 -6.73 
DB00807 -6.71 
DB08170 -6.71 
DB01070 -6.69 
DB02946 -6.66 
DB08302 -6.65 
DB08105 -6.64 
DB01505 -6.63 
DB07446 -6.63 
DB07772 -6.62 
DB08379 -6.60 
DB08690 -6.57 
DB01134 -6.55 
DB04773 -6.52 
DB07160 -6.52 
DB01892 -6.51 
DB02791 -6.51 
DB04317 -6.50 
DB04674 -6.48 
DB00596 -6.44 
DB01130 -6.42 
DB01819 -6.39 
DB04572 -6.35 
DB04693 -6.35 
DB03520 -6.28 
DB04657 -6.26 
DB00261 -6.23 
DB01410 -6.14 
DB00976 -6.08 
DB04534 -6.05 
DB04093 -6.04 
DB03554 -6.01 
DB02095 -5.98 
DB04580 -5.96 
DB03793 -5.80 
DB04299 -5.79 
DB03110 -5.73 
DB02721 -5.66 
DB04553 -5.64 
DB04619 -5.64 
DB02922 -5.49 
DB01701 -5.44 
DB04179 -5.43 
DB00732 -5.20 
 
No. of compounds with estimated free energy of binding (<= -8.00 kcal/mol) = 55 
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5 Discussion 
Screening of 6160 compounds from DrugBank database using various filters 
namely pharmacophore search, predicted biological activity (IC50) and docking study was 
carried out. At the end of each screening a significant amount of compounds of non-
interest were eliminated from the overall screening process. There were 721 compounds 
after application of pharmacophore screen. After the application of biological activity 
screen 498 compounds were taken for further screening. These compounds were screened 
based on the estimated free energy of binding (∆G) after being subjected to docking 
study.Finally, 54 compounds were left. These compounds belonged to various classes 
namely Phenylpropenes, Phenethylamines, Anisoles, Alkaloids and Alkaloid Derivatives, 
Steroids and Steroid derivatives, Phenylpropylamines, Salicylates and Derivatives, 
Benzenesulfonamides, Pyrans, Lactones, Benzamide, Purine and purine derivatives, 
Piperazines, Halobenzenes, Biphenyltetrazoles and Derivatives, Aminoglycosides, 
Chromones and Diphenylmethanes. Of these classes of compounds a few have already 
been associated with inhibition of gamma-secretase namely sulfonamides (61, 98, 99, 109). 
The occurrence of this class of compounds in the study reaffirms the potential of these 
compounds. Also a few of the compounds classes have not yet been reported as potential 
inhibitors of gamma secretase namely piperazine, phenylpropylamine, and anisoles. Also a 
few of the hits are anti-hypertensive drugs. This class of drugs has already been studied for 
therapy of Parkinson’s disease(116). Despite the differing mechanisms of pathogenesis of 
Alzhiemer’s disease and Parkinson’s disease, it is inferred that further study of anit-
hypertensive drugs for development of therapy of Alzheimer’s may produce potential 
drugs. Further study of these classes of compounds may produce a novel class of 
inhibitors of gamma secretase. Thus it may aid in the therapy of Alzheimer’s disease. 
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